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ABSTRACT  
Susan Elizabeth Wilson: Implementation and Evaluation of Depression Improvement 
Program in Stroke Care (DIPS) 
(Under the direction of Mary Lynn Piven) 
Background: Post-stroke depression (PSD) is a serious complication of stroke. It often goes 
undetected and untreated.  
Purpose: The primary objective was to evaluate utilization of the Patient Health Questionnaire-9 
(PHQ-9), depression treatment algorithm and development of a treatment plan. Secondary 
objectives were to (1) evaluate timing of PHQ-9 (2) compare the relationship between PSD, 
severity of stroke, functional disability and discharge location and (3) evaluate patient reported 
PHQ-9 and proxy family member caregivers results and (4) determine staff satisfaction with 
project implementation.  
Methods: In an observational study, 85 consecutive ischemic stroke (IS), hemorrhagic stroke 
(ICH), subarachnoid (SAH), and transient ischemic attack (TIA) patients consented to participate 
during admission between March and August 2017. Patients and proxy caregivers completed the 
PHQ-9 within the first 48 hours of admission, post-discharge day 7, and post-discharge day 30 to 
assess for depression. The modified Rankin Score (mRS) assessment tool was used to evaluate 
functional disability pre-stroke and at discharge.  
Results: Subjects were diagnosed with IS (n=68), ICH (n=15), SAH (n=1) and TIA (n=1). 
During admission, 47.1% reported depression symptoms. There were 16 (p=0.053) incident 
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cases at day 7 and 13 (p=0.0046) incident cases at day 30. 37.5% were treated during admission 
based on the initial PHQ-9 score, p=0.0005. Forty-two percent were treated by discharge, 
p=0.0002. 43.6% were treated by day 7, p=0.0007 and 40.5% treated by day 30, p=0.0002. A 
significant increase in reported PHQ-9 score from baseline admission occurred later during 
admission, p=0.0046 and a moderately positive relationship existed between patient reported 
PHQ-9 and proxy, p<0.0001. A significant relationship occurred between reported minor 
depression and discharge to a skilled nursing facility (p=0.0163).  
Conclusions: This study suggests that implementation of an evidenced-based depression 
screening and treatment algorithm can improve detection of depression symptoms and treatment 
of PSD during the acute phase of hospitalization. Patients reported a significant increase in 
depression symptoms later in the admission and there is moderately positive relationship 
between patient reported PHQ-9 scores and proxy caregiver. Assessment and treatment of PSD 
during acute hospitalization with follow-up after discharge should be standard of care for all 
stroke sub-types.  
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CHAPTER 1: INTRODUCTION 
Stroke effects approximately 800,000 people each year in the United States and is the 
number one reason of disability (American Heart Association/American Stroke Association, 
2017).  Post-stroke depression (PSD) is a serious complication occurring in at least 36% of 
patients during the acute and rehabilitation phase (Paolucci, 2008). Comparatively, the estimated 
prevalence of major depressive disorder in the United States among the general adult population 
is 6.7% (NIMH, 2015). PSD is significantly associated with a negative impact on recovery 
(Hadidi, Lindquist, Treat-Jacobson & Savik, 2011), higher hospital costs (Husaini, et al, 2013), 
and increased mortality (Robinson & Jorge, 2016).   
Approximately one-third of stroke survivors will experience depression at any time point 
after stroke diagnosis (Towfighi, et al, 2016; Robinson & Jorge, 2016; Paolucci, 2008). Research 
suggests a link between depression and risk of stroke. We know depression worsens chronic 
diseases, such as cardiovascular disease, hypertension and diabetes, increasing the risk of stroke. 
However, the direction of this association is not completely understood (Del Zotto, et al., 2014). 
Further a significant bidirectional relationship between PSD and severity of functional disability 
exists, negatively influencing recovery (Hadidi, Treat-Jacobson & Lindquist, 2009; Robinson & 
Jorge, 2016; Towfighi, et al, 2016) and increasing discharge to an institution versus to home 
(Kramer, Holthaus, Goodrish & Epstein, 2006). Research has shown treatment of PSD or 
resolution of PSD symptoms positively influences recovery (Chollet, et al., 2011; Nannetti, Paci, 
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Pasquini, Lombardi & Taiti, 2005). Therefore, recognizing and treating preexisting and post-
stroke depression may represent an untapped opportunity to significantly improve stroke 
recovery.  
Stroke severity and functional disability is a predictor of PSD (Robinson and Jorge, 2016) 
with higher levels of functional disability found in severely depressed patients (Schmid, et al., 
2011). However, the impact of PSD may be independent of the severity of stroke disability. Shi 
et al. (2015) followed 747 patients with a diagnosis of minor stroke for one year and found 
26.5% developed PSD. Although the patients had lower rates of disability, the PSD positive 
patients were less likely to recover from the functional disability compared to patients without 
PSD symptoms, suggesting that depression poses a risk to functional improvement regardless of 
disability severity (Zikic et al., 2014). PSD undermines a patients’ motivation to engage in 
rehabilitation, which is especially critical during the acute recovery phase when it is important to 
participate in rehabilitation.  
The majority of stroke survivors affected by PSD are undiagnosed and under-treated 
during hospitalization (Gaete and Bogousslavsky, 2008). PSD may be under-recognized due to 
shorter length of stays, passive attitude of medical personnel toward diagnosis, patient and health 
care worker inability to recognize depression symptoms, difficulty of patient assessment, or 
physician concern about adverse side effects of treatment (Gaete and Bogousslavsky, 2008; 
Hollender, 2014; Paolucci, 2008). Further, clinicians are unsure of the appropriate time to screen 
during hospitalization. The literature suggests antidepressant medications are beneficial in 
treating PSD and improving motor recovery (Towfighi, et al., 2016; Chollet, et al., 2011) through 
positive effects on neuroplasticity and neurogenesis (Flaster, et al., 2013; Siepmann, et al., 2015). 
Additionally, trials published since 2007 suggests there may be a benefit to treating PSD with 
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psychotherapy (Towfighi, et al., 2016) but lack animal model research exploring the biological 
response of PSD to psychotherapy (Loubinoux, et al., 2012). Yet, many stroke centers do not 
provide depression screening, leading to under-identification and under-treatment (Hermann, et 
al., 2011).  El Husseini, et al. (2012) found 67.9% of ischemic stroke patients and 70% of TIA 
patients with PSD not treated at three-month and twelve-month evaluations. Thus, improving 
screening for PSD among stroke centers is an essential component of early recognition.  
The high prevalence of PSD and increased risk for poor outcomes sparked the American 
Heart Association/American Stroke Association to publish a scientific statement paper 
addressing PSD, providing guidance for clinical practice and further research (Towfighi, et al., 
2016). Additionally, certifying bodies such as The Joint Commission (TJC) acknowledge the 
importance of detecting PSD during hospitalization (The Joint Commission, 2017). 
Background and significance 
UNC Health Care is a 900-bed academic medical center certified by The Joint 
Commission as a Comprehensive Stroke Center (CSC). This prestigious designation recognizes 
hospitals that meet rigorous quality measures and standards in treating complex stroke patients. 
One standard requires CSCs to evaluate stroke survivors for depression during hospitalization.  
In order to meet TJCs standard for depression screening, the UNC stroke center 
implemented the Patient Health Care Questionnaire-2 (PHQ-2) in 2011. Nurses screened patients 
upon admission by asking two questions, ‘if experience little interest in doing things’ and ‘if 
feeling down’, and documented the results in the medical record. The stroke center did not have 
a protocol to guide care actions in response to positive assessments for stroke. The PHQ-2 was 
embedded within the electronic medical record, EPIC, only nursing knew where and how to 
access the results. This screening occurred less than 60% of the time, lacked a mechanism to 
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notify the physicians, and therefore did not translate into a treatment plan of care by the 
neurology or neurosurgical treatment teams.  
A common theme emerged during post-discharge patient follow-up phone calls by the 
stroke nurse practitioner (NP). Many stroke survivors reported symptoms of depression and no 
desire to participate in rehabilitation. Most patients were not aware of PSD nor were they 
receiving treatment. The potential need for a quality improvement response prompted the stroke 
center to evaluate the prevalence and incidence of PSD in patients treated at UNC Health Care. 
The center subsequently conducted a longitudinal observational study.  
Findings from this study identified areas for care improvement. From July 2014 to 
January 2017, 271 inpatient subjects recruited during the acute treatment period were screened 
for PSD symptoms (minor and moderate to severe). Researchers found that 33-55% of stroke 
patients (transient ischemic attack (TIA) 33.3%, ischemic (IS) 47.8%, intracerebral hemorrhage 
(ICH) 46.9%, and subarachnoid hemorrhage (SAH) 55% (Figure 1.1) exhibited depressive 
symptoms. Yet, only 21.4% (p=0.0054) received treatment upon discharge requiring many 
patients to start treatment during rehabilitation, potentially delaying response and recovery 
(Wilson unpublished, 2017).  When compared to the literature, UNC patients self-reported 
higher rates of symptoms. The study team attributed these rates to several potentially 
confounding factors: (1) inclusion of hemorrhagic strokes and those with mild aphasia, (2) 
subjects with a history of depression and (3) the possible timing of the performed assessment. 
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Figure 1.1: Percentage of Reported Minor and Major PSD Symptoms by Stroke Category 
(Minor = PHQ-9 score 5-9 and Moderate to Severe = PHQ-9 score > 10) 
 
 
 
Purpose of Project 
Because of the existence of a detection and treatment disparity in stroke patients treated 
by UNC neurology and neurosurgery and the inverse relationship between PSD and recovery, the 
purpose of the doctoral of nursing practice (DNP) project, Depression Improvement Program in 
Stroke (DIPS), was to fill the identified gap.  
The DNP project developed, implemented and evaluated an early detection and treatment 
algorithm, to determine if an evidenced based protocol would standardize psychiatric care for 
acute stroke patients and improve detection and treatment. DIPS replaced the PHQ-2 with the 
PHQ-9, allowing improved detection and development of a treatment plan. DIPS targeted 
communication between nurses and physicians, to improve notification of PHQ-9 scores. 
Implementation of DIPS sparked improved PSD education for patients and their caregivers 
through the addition of PSD information added to the stroke education booklet.   
ICH (n=47) Ischemic (n=163) SAH (n=40) TIA (n=21)
Minor Depression 19.2 26.9 27.5 19.1
Major Depression 27.7 20.9 27.5 14.3
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The evidence-based quality assessment (EBQA) methodology (Melnyck and Fineout-
Overholt, 2014) provided program guidance, including outcome measures, targeted at (1) 
utilization of the screening tool and fidelity to DIPS treatment algorithm, (2) patient depression 
and functional status, (3) timing of PHQ-9 screening, (4) staff satisfaction with the DIPS process 
and (5) compare pre- and post-project implementation data. Because patients with aphasia or 
communication limitations are difficult to assess and are often excluded from research evaluating 
PSD, this study evaluated the correlation between patient-reported PHQ-9 and proxy caregiver-
reported PHQ-9. If a correlation exists, nurses and physicians may use a proxy to screen, 
overcoming barriers to assessment and determine the patient treatment plan.  
Project Question 
 Will DIPS standardize and improve detection and treatment with adherence to best 
practice recommendations? Will DIPS standardize roles, integrate the care team and provide 
patient-centered care using existing staff? 
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CHAPTER 2: REVIEW OF LITERATURE 
Review of evidence 
A review of the literature incorporated relevant literature and a theoretical framework for 
evaluating PSD. A computer-aided search of studies published in English was conducted in the 
following online databases: PubMed, CINAHL, the Cochrane Library and PsycINFO. Various 
combinations of the following key words included: stroke, cerebral infarction, cerebral 
hemorrhage, depression, post-stroke depression, early, treatment, acute, screening, prevention, 
prophylaxis, hospitalization, recovery, and antidepressants. Utilizing the words stroke or 
depression alone revealed an overwhelming quantity of articles, leading to the narrower search to 
identify relevant post-stroke depression articles.  
Inclusion/Exclusion Criteria 
For this review, inclusion criteria included the following: articles published after 2001, 
patients with stroke diagnosis, diagnosed with depression based on Diagnostic and Statistical 
Manual of Mental Disorders (DSM) criteria or a validated depression symptom rating scale, 
adults (age > 18), early treatment of depression (< 1 month) and evaluation for improvement in 
deficits (functional outcome). Exclusion criteria included: (1) non-stroke diagnosis, (2) pediatric 
(age < 17), and (3) treatment started > 3 months after stroke diagnosis. 
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Results 
Of the 126 eligible full-text articles, 105 were excluded based on wrong outcome, design, 
timing or duplication. The remaining studies included in this review ranged from a Cochrane 
review as well as evidence-based guidelines (Appendix 1).  
Twenty-one articles were included: (1) one Cochrane Review, consisting of 52 
randomized controlled trials (RCTs), (2) three additional RCTs not captured in the Cochrane 
Review, (3) eight non-randomized prospective studies, (4) three systematic reviews, (5) two 
evidence-based guidelines, (6) a meta-analytical analysis of the literature, (7) two longitudinal 
studies based on registry data, and (8) an observational study. A recently published statement by 
the American Heart Association on PSD was also included. Amid the rich literature, the 
following themes emerged: (1) prevalence and incidence of PSD, (2) associated risk factors, (3) 
mortality, (4) PSD and functional assessment tools, (5) PSD screening, (6) relationship between 
PSD and functional status, (7) treatment, (8) timing of treatment from stroke onset, and (9) effect 
of treatment on PSD and functional outcomes.   
Scope of the Problem 
 Prevalence and incidence of PSD.  Depression is a common sequela of stroke. Rates 
vary depending on clinical setting, with the highest rates occurring in the acute and subacute 
rehabilitation stage (Salter, et al, 2016). Pooled data revealed an overall mean prevalence of 
35.5% for major depression among acute in-patient stroke survivors and in the rehabilitation 
setting, while 31.8% occurred in the outpatient community setting (Salter, et al, 2016). PSD 
symptoms persist. In a five-year population based study of 3,689 stroke survivors, Ayerbe, Avis, 
Wolfe and Rudd (2013), found PSD prevalence of 33% at three months, 28% at one year, 32% at 
3 years, and 31% at five years.  
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 Risk factors.  Although PSD is common, there remains uncertainty to its etiology and 
risk factors. Much of the difficulty with determining clear risk factors lies within the 
methodological limitations of the studies, such as exclusion of patients with hemorrhagic stroke, 
aphasia or dementia, insufficient sample size preventing multivariate analysis and poor statistical 
methods (Towfighi, et al., 2016). However, pooling the literature from 1990 to present, the most 
common risk factors identified include a history of depression, stroke severity, functional 
disability, cognitive impairment and social isolation (Salter, et al., 2016). Age, sex and 
socioeconomic status produced inconsistent results in the literature, yet, a trend shows females 
and older age may be at increased risk, with younger age associated with anxiety and suicide 
(Salter, et al, 2016).    
 Additionally, an abundant number of studies have evaluated the location of stroke lesion 
as a predictor of PSD. Currently, the relationship between PSD and lesion location remains 
controversial. Several systematic reviews and meta-analyses found no definitive connection 
between lesion location and risk for PSD (Salter et al, 2016).  
Mortality.  PSD is associated with increased mortality. Everson, Roberts, Goldberg, and 
Kaplan (1998) linked the presence of depression symptoms with an increased risk of death 
through their community-based study of 6,676 adults with no history of stroke, followed over 29 
years. Using the Human Population Laboratory Depression Scale, they found that for each point 
increase, there was an associated 8% increase risk of mortality. A systematic review of 13 
studies involving 59,598 subjects confirmed Everson’s findings. The pooled odds ratio (OR) for 
post stroke mortality in patients with depression was 1.22 (95% confidence interval (CI), 1.02-
1.47) (Bartoli, et al, 2013).   
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Mortensen, Johnsen, Larsson and Andersen (2015) evaluated all-cause 30-day mortality 
in stroke patients treated with antidepressants during admission compared to patients not treated.  
The population-based study reviewed 5,070 consecutive first-time stroke patients without prior 
antidepressant use in the Danish Stroke Registry from 2003 to 2010. The adjusted OR of 30-day 
mortality was 0.28 (95% CI, 0.18-0.43) for patients treated during admission compared to 
patients not treated indicating early treatment with antidepressants was safe (Mortensen, 
Johnsen, Larsson, & Anderson, 2015).  
PSD Assessment Tools.  Because PSD impedes functional recovery, increases mortality 
and affects quality of life, international guidelines recommend screening for PSD throughout the 
continuum of care (Eskes, et al, 2015). Despite the recommendation, inconsistent evaluation of 
PSD may be the reason for the variation in prevalence. Regardless, the gold standard for 
diagnosing depression is the Diagnostic and Statistical Manual of Mental Disorders, currently in 
its fifth edition (DSM-5). However, this level of diagnostic evaluation is challenging during the 
acute phase due to short lengths of admission and lack of access to mental health professionals 
able to perform the evaluation (Burton & Tyson, 2015).  
The literature suggests a range of tools for use in screening PSD. Meader, Moe-Byrne, 
Llewellyn, and Mitchell (2014) performed a meta-analysis of screening tools to determine 
accuracy.  The authors found three scales, Center of Epidemiological Studies-Depression Scale 
(CES-D), Hamilton Depression Rating Scale (HDRS), Patient Health Questionnaire-9 (PHQ-9), 
to be the most favorable choices in the stroke population (Appendix 2). The PHQ-9, used in the 
DIPS project, is a nine-item questionnaire measuring the nine symptoms of depression based on 
DSM criteria. Questions are scored based on a four-point Likert scale with total scores ranging 
from zero to 27 (zero = no depression symptoms, 1-4 = minimum depression symptoms, 5-9 = 
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mild depression symptoms, 10-14 moderate depression symptoms, 15-19 = moderately severe 
depression symptoms and 20-27 = severe depression symptoms. The PHQ-9 performed well in 
regard to sensitivity (0.86) and specificity (0.79). Using clinical utility index (CUI) analysis, the 
PHQ-9 had high applicability (0.58) for identifying PSD (Meader, Moe-Byrne, Llewellyn, & 
Mitchell (2014). For purposes of this study, minor depression was defined as a PHQ-9 score of 
5-9 and moderate to severe depression as a PHQ-9 score of > 10.  
Functional Status Assessment Tools. Salter et al. (2013) evaluated reliability, validity 
and responsiveness among tools commonly used to measure outcomes in stroke rehabilitation.  
Because there are many measurements of functional status, for purposes of this report only the 
Barthel Index (BI), Functional Independence Measure (FIM), Fugl-Meyer Assessment of Motor 
Recovery after Stroke (FMA), Modified Rankin Score (mRS) and National Institutes of Health 
Stroke Scale (NIHSS) will be referenced due to their extensive use in stroke research and clinical 
practice (Appendix 3).  
The two tools used in the DIPS study were the mRS and the NIHSS. The mRS is a 
universal outcomes scale based on level of independence and used extensively in clinical trials as 
a primary outcome measure. It is an ordinal scale ranging from no symptoms (score = 0) to death 
(score = 6). It has excellent reliability and validity (sensitivity, 0.85 and specificity, 0.87). The 
NIHSS is a physical assessment tool used to measure the severity of symptoms and quantify 
neurological deficits associated with stroke and used extensively in the clinical setting by 
emergency and neuroscience providers and in clinical research trials as a primary outcome. 
Scores range from zero (no deficits) to 42 (extremely severe deficits). It has adequate reliability 
and excellent validity ratings (sensitivity 0.72, and specificity, 0.89) (Salter, et al, 2013). 
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PSD Screening. Stroke deficits, such as aphasia, cognitive limitations, unawareness or 
denial, present challenges to diagnosing depression. Limitations exist with current screening 
tools and the most appropriate tool for PSD screening remains unclear. In addition, establishing 
the appropriate timing of screening and if PSD screening improves outcomes, remains to be 
determined (Towfighi, et al., 2016). Despite these uncertainties, several international guidelines 
(British Psychological Society, US Preventative Services Task Force, and Canadian Stroke 
Guidelines), support PSD screening and the American Heart Association/American Stroke 
Association rehabilitation guidelines recommend screening and treatment (McIntosh, 2017).  
Patients with aphasia and cognitive impairment are often unable to complete screening 
assessments and present challenges for screening and treatment decision making. Yet, these 
impairments are significant predictors of PSD (Salter, et al., 2016). Previous work suggests a fair 
to moderate correlation between patient and family proxy PHQ-9 scores (Pearson r=0.53, 
p<0.001) (Williams, et al., 2006; Skolarus, et al., 2010). Therefore, obtaining information from a 
proxy may be preferable to obtaining no information. 
Relationship between PSD and Functional Status. Approximately 14% of stroke 
survivors fully recover while 25-50% require some level of assistance with activities of daily 
living (Hadidi, Lindquist, Treat-Jacobson and Savik, 2011). The relationship between PSD and 
functional disability is bidirectional. Robinson and Jorge (2016) evaluated six studies, affirming 
that severity of PSD is an independent predictor of stroke severity and related to functional 
impairment. Nannetti, Paci, Pasquini, Lombardi and Taiti (2005) evaluated 117 stroke patients 
with 49 diagnosed with PSD. The Fugl-Meyer Assessment, scores were significantly better in the 
PSD negative group compared to the PSD positive group (p < 0.05). In addition, the Barthel 
Index scores, at three to four weeks post stroke were significantly better in the PSD negative 
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group (p < 0.05). Although most studies report higher levels of functional disability in more 
severely depressed patients, others have found the impact to be independent of severity, 
suggesting that depression poses a risk to functional improvement in all stroke patients 
regardless of disability severity (Zikic, et al, 2014). Shi et al, (2015) followed 747 first-ever 
minor stroke patients for one year with the goal of investigating the association between PSD 
and disability in minor stroke. The authors found that PSD was significantly associated with a 
risk of disability (OR 4.12, 95% CI 2.13-7.90). In patients with PSD at admission and at the six-
month follow-up, but not at the one-year period, still had a higher risk of disability (OR 2.83, 
95% CI 1.28-6.21) compared to the non-PSD patients. Additionally, over the one-year follow-up 
period, PSD positive patients had a higher stroke recurrence rate compared to PSD negative 
patients (9.1% vs 4.4%, p = 0.027). 
Treatment. In animal studies of ischemic stroke, selective serotonin reuptake inhibitors 
(SSRI) improved stroke volume through mechanisms of enhanced neuroplasticity, improved 
cerebral blood flow and anti-inflammation mediated neuroprotection. Yet, the role of these 
mechanisms remain unclear in human stroke patients (Siepmann, et al., 2015). Documentation of 
pharmacological and non-pharmacological methods of treating PSD exists in the literature. The 
most studied drug treatments include selective SSRI and tricyclic antidepressants (TCA) (Salter 
et al, 2016). Seven studies evaluated SSRIs for treatment effectiveness based on psychometric 
scales measuring severity of depression symptoms. Time to follow-up in the studies ranged from 
6.5 to 26 weeks. Citalopram significantly decreased depression symptoms by 0.54 (p = 0.03) 
standard mean deviation (SMD) compared to the placebo group during six weeks follow-up. 
Whereas, sertraline did not have the same effect (SMD = 0.17, p = 0.36) during a 26-week 
treatment period. Five trials evaluating fluoxetine found mixed results. The largest effect was 
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observed during 6.5 to 8 weeks follow-up with the treatment group experiencing a SMD of 0.79 
(p = 0.03) decrease in depression symptoms compared to placebo and a SMD of 1.14 (p = 0.00) 
decrease after 8 weeks of treatment. However, after 12-weeks of treatment, there was only a 
modest difference between the treatment group compared to placebo (SMD = 0.16, p = 0.56) 
(Wannagat, Zielasek & Gaebel, 2013). Additionally, the FLAME trial found use of the SSRI, 
fluoxetine, improved motor recovery compared to those that did not receive fluoxetine (Chollet, 
et al., 2011). A Cochrane Review evaluating selective serotonin reuptake inhibitors (SSRIs) for 
stroke recovery did not find a significant excess of seizures, gastrointestinal side effects or 
hemorrhage in the patients randomized to SSRIs. The review reported the following risks 
associated with SSRI’s: (1) RR for death was 0.76 (95% CI, 0.34 to 1.70), (2) RR for seizure was 
2.67 (95% CI, 0.61 to 11.63), (3) RR for gastrointestinal side effects was 1.90 (95% CI, 0.94 to 
3.85) and (4) RR of bleeding was 1.63 (95% CI, 0.20 to 13.05) (Mead, et al., 2012).  
 Seven studies evaluated the effects of nortriptyline (TCA), reboxetine (selective 
noradrenaline reuptake inhibitor-SNRI), trazodone (serotonin antagonist and reuptake inhibitor-
SARI) and free and easy wanderer plus (FEWP), an herbal drug, with a follow-up period ranging 
from 6.5 to 16 weeks. In patients taking nortriptyline, depression scores were significantly lower 
compared to the placebo group (SMD = 1.05, p = 0.02). Reboxetine had a significantly lower 
mean depression severity score compared to placebo (SMD of 3.0, p = 0.000), while trazodone 
resulted in 1.23 (p = 0.007) SMD less depression and FEWP showed similar results of 1.32 (p = 
0.000) less depression symptoms compared to placebo (Wannagat, Zielasek & Gaebel, 2013).   
 Studies evaluating non-pharmacological interventions included cognitive behavioral 
therapy (CBT), ecosystem-focused therapy (EFT), exercise, care management and transcranial 
magnetic stimulation (rTMS). There was no significant difference between patients treated with 
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CBT versus attention-placebo sessions (p = 0.5). EFT produced questionable results, with a 
SMD of 0.79 (p = 0.06) indicating a treatment effect even though there was no statistical 
significance. Likewise, there was no improvement in the exercise group (SMD = 0.17, p = 0.49).  
Nonetheless, the Activate-Initiate-Monitor (AIM) care management model, which taught the 
patient and family to recognize symptoms of PSD, start antidepressants and provided monitoring 
for medication adjustment, found significant improvement in depression symptoms compared to 
standard of care, stroke education without discussion of depression and treatment left to treating 
physician discretion (51% versus 30%, p = 0.005) (Williams, et al, 2007). Additionally, rTMS 
was superior to sham (placebo). In patient’s receiving 12,000 pulses, a 31% decrease in HDRS 
was recorded compared to 13.6% in the placebo group (p = 0.04). In patients receiving 18,000 
pulses, HDRS scores decreased by 42.4% compared to 17.5% in the placebo group (p < 0.001) 
(Wannagat, Zielasek & Gaebel, 2013).   
 Time of treatment from stroke onset. Research suggests a benefit of antidepressants on 
neuroplasticity and neurogenesis, promoting the development of neurons to improve function 
and survival (Flaster, Sharma & Rao, 2013). One hypothesis is that brain injury from a stroke 
creates an inflammatory response provoking the development of PSD. SSRIs have an anti-
inflammatory effect on the dopaminergic pathways that mitigate the effects of PSD. The early 
reduction of inflammation may provide a protective effect on neurons by reducing brain 
ischemia and further neurological deterioration (Siepman, et al, 2015).  
 Narushima and Robinson (2003) evaluated early (19 +/- 25 days) versus late (140 +/- 28 
days) use of antidepressants in the treatment of PSD. There was no significant difference 
between the study groups, even though the early treatment group had a slightly lower FIM score 
(more disabled). The authors reported a significant improvement in the group treated early 
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compared to the late treatment group based on FIM scores (p < 0.05). Additionally, the early 
treatment group continued to improve over the two-year follow-up, while the late treatment 
group deteriorated (early treatment group FIM scores: 59.0 at three months, 61.6 at one year and 
62.4 at two years; late treatment group FIM scores: 58.2 at three months, 59.5 at one year and 
56.7 at two years) (Narushima & Robinson, 2003).  
Effect of treatment on PSD and Outcome. PSD has a negative impact on functional 
and cognitive recovery (Salter, et al, 2016). Schmid, et al, (2011) reported baseline depression 
severity, stroke severity and medical comorbidities, as three features of PSD influencing 
functional dependence. The authors found a significant difference in PHQ-9 scores among the 
depressed group at 12-weeks. Patients that were functionally dependent scored 9.94 versus 
patients that were functionally independent scored 7.27, p = 0.019.  
To determine the effects of SSRIs on functional outcome, a Cochrane Review of the 
literature was performed (Mead, et al., 2012). Fifty-two trials (n=4,060 subjects) were included 
in the meta-analysis. Thirty-six trials recruited subjects within 0-3 months post-stroke, four at 3 
to 6 months, two at 6 to 9 months and 10 did not report timing. Primary outcomes were 
dependency (measured by the mRS) and disability (measured by different scores such as BI or 
FIM). Secondary outcomes were neurological impairment (measured by various deficit scores 
such as the NIHSS). SSRIs were associated with less disability versus controls (SMD = 0.92, 
95% CI, 0.62 to 1.23), better neurological recovery (SMD = 1.00, 95% CI, -1.26 to -0.75) and 
improved depression symptoms (SMD = 1.92, 95% CI, -2.34 to -1.48). Limitations with the 
Cochrane included considerable heterogeneity between the trials (Mead, et al., 2012).   
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Conclusions  
This literature review provides evidence of a benefit of selective serotonin reuptake 
inhibitors (SSRIs) in reducing disability in stroke patients when treated during the acute phase, 
but the degree of benefit remains unclear (Eskes, et al., 2015; Mead, et al., 2012; & Narushima & 
Robinson, 2003). In current practice, SSRIs are not routinely prescribed with the goal to improve 
recovery or prevent depression. Yet, given the prevalence of PSD, associated mortality and the 
negative impact on recovery, screening and treatment should be considered in all stroke patients.  
Recently published stroke rehabilitation guidelines, recommend patients diagnosed with PSD be 
treated with antidepressants (class l, level of evidence B) (Winstein, et al., 2016). Therefore, it is 
reasonable to start treatment during hospitalization, with the goal of improving disability and 
depression symptoms.   
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CHAPTER 3: THEORETICAL FRAMEWORK 
A search for nursing theory related to PSD used various combinations of post-stroke 
depression, nursing theory, theory, construct, nursing model, model, nursing framework, and 
framework occurred. The search for nursing theory related to PSD produced 223 articles, of 
which only three were relevant to the topic.  
Scientific underpinnings 
Doctoral of nursing practice (DNP) graduates rely on a diverse scientific foundation to 
guide practice. This foundation includes teachings from biology, physiology, psychology, social 
sciences and philosophy (AACN, 2006). Nursing theory includes these sciences to formulate and 
give meaning to the nursing perspective and practice. PSD affects stroke survivors medically, 
physically, psychologically and socially (Mast & Vedrody, 2006). DIPS uses the Depression and 
Functional Status in Stroke Survivors (DFSSS) model (Appendix 4) which has underpinnings in 
biology, psychology and social sciences as a theoretical framework to provide justification for 
evaluation and intervention.  
Theory of the problem 
PSD and functional disability have a bidirectional relationship. The higher the level of 
disability, the higher the level of depression symptoms and risk for PSD (Hadidi, Lindquist, 
Treat-Jacobson & Savik, 2011). This relationship may be regarded within the biopsychosocial 
model. Engel’s biopsychosocial model of health and illness considers the interactions between 
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biological, psychological and social factors in understanding the cause and health care response 
to illness (Engel, 1977; Engel, 1980). The majority of research focuses on the biomedical 
etiology of PSD and pharmacologic recommendation for treatment. The biomedical etiology 
incorporates the hypotheses of stroke lesion location, neuro-inflammation, neuroplasticity, and 
genetics (Mast & Vedrody, 2006; Mittal, Hum & Schallert, 2016). Because of this focus, it is not 
surprising that pharmacologic intervention is the first choice of treatment for PSD. Although 
most patients respond to antidepressants (67.5%), a substantial number continue to exhibit PSD 
while on therapy (Eriksson, et al, 2004). These non-responders suggest that alternative 
approaches to understanding and treating PSD is necessary and the inconsistent results seen in 
the biomedical approach are possibly linked to psychosocial factors. The literature is lacking in 
addressing the consequences of psychosocial factors in prevention and treatment of PSD.  
Therefore, a biopsychosocial approach to PSD, addressing the early neuroanatomical damage 
and later stages of stroke sequelae associated with functional limitations of activities of daily 
living is indicated (Mast & Vedrody, 2006). A sufficient model considers both the early 
biological effects of stroke and the later stroke sequelae, such as functional impairments, leading 
to PSD with strategies targeted at both phases.   
Theory of intervention 
The conceptual model, DFSSS, supports the relationship between the biopsychosocial 
effects of PSD and functional status while treatment targets the negative effects associated with 
depression and functional disability. Treatment considers both early and later stages of PSD 
through utilization of pharmacologic and rehabilitation strategies (Alfred & Beard, 2002).   
Two nursing scientists, Danita Alfred, PhD, RN and Margaret T. Beard PhD, RN, 
developed the DFSSS Model to predict the relationship between PSD, functional status and 
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intervening strategies of rehabilitation and antidepressant treatment. The model begins with 
depression representing the psychological aspect and functional status representing the biological 
aspect. Intervening treatment strategies attempt to mitigate the effects of depression and 
functional disability. The predictive theory proposes that PSD and decreased functional status are 
related and interventions can positively influence patient outcomes on both biological and 
psychological levels (Alfred & Beard, 2002).  This too is the premise of DIPS.  
DFSSS is derived from Engel’s biopsychosocial model and Huber and Oermann’s Model 
of Outcome Initiative amidst influences from the medical, social, psychological, and outcome 
sciences (Alfred & Beard, 2002; Engel, 1980; Huber & Oermann, 1999). The biopsychosocial 
model component attempts to decrease the antagonistic biological and psychological 
perspectives by assimilating the understanding of how PSD may stem from functional disability 
and psychosocial response (Pedroso, Souza, Brunoni, & Teixeira, 2015). The model of Outcome 
Initiative captures quality outcomes by incorporating patient, clinician, organizational and 
community characteristics influencing health care delivery, which in turn impact patient, 
clinician, organizational and population outcomes (Huber & Oermann, 1999).   
Meta-analytic techniques, showing a significant relationship between depression and 
decreased functional status, tested the DFSSS model. Forty-five research studies, five of which 
were randomized controlled trials, examined the effect size between depression and functional 
status. The binomial effect size display suggested that PSD treatment and rehabilitation could 
improve levels of function from 29% to 71%. The authors concluded that there is a significant 
relationship between elevated levels of depression and low levels of function. Additionally, the 
researchers determined pharmacologic treatment and rehabilitation significantly impact the 
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negative relationship between depression and functional status (Alfred & Beard, 2002), which 
continues to be supported in the literature (Mead, et al, 2012). 
Extensive literature discusses biological theories on the pathophysiology of PSD and 
ample literature presents the opposing psychological perspective. This polarity may be part of the 
problem with developing a comprehensive approach, as PSD is not purely biological or 
psychological, but multifactorial and more consistent with the biopsychosocial model. The 
DFSSS model may appeal to diverse health care providers (such as, physicians, nurses, social 
workers, and mental health providers) because of its foundation in outcome science and 
biopsychosocial theory and thus, is a strength of the model. Although, 45 studies tested the 
model, it lacks a reference in the stroke literature or further testing after 2002.   
Yet, the DFSSS model is relevant to caring for the stroke survivor with PSD. The 
simplicity of the framework incorporates the complex relationship between depression and 
functional status, implying that treatment of the disease process requires the clinician to address 
the biological, psychological and social influences to improve patient outcomes. This model is an 
acceptable framework to guide the implementation of DIPS.   
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CHAPTER 4: METHODOLOGY  
Improvement strategy 
The Institute of Medicine defined six aims of health care quality, recommending that 
patient care be timely, effective, efficient, patient centered, safe and equitable (Institute of 
Medicine, 2001). The primary aim of DIPS is to decrease the gap in PSD detection and treatment 
by focusing on timeliness and efficiency with the ultimate goal of effectiveness. DIPS is patient 
centered and equitable (involving all categories of stroke) and safe with close follow-up post 
discharge.   
Evidence Based Practice Change 
The DIPS team applied the evidence-based quality assessment (EBQA) methodology, 
similar to the plan-do-study-act methodology, to implement the changes. EBQA utilizes an 
evidenced based guideline approach to influence performance, which has been successful in 
driving physician behavior in stroke care (Smith, 2000). Use of 3A gap analysis determined the 
need for DIPS (Table 4.1).    
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TABLE 4.1: 3A GAP ANALYSIS 
Reason for Action Gap Analysis Completion Plan 
1. High incidence of PSD 
2. Assessment failures 
3. Missed treatment 
opportunities 
 
Patients with PSD have poor 
recovery, decreased quality of 
life, increased mortality and 
higher medical costs 
1. Short lengths of stay 
2. Health care team does not 
recognize PSD symptoms 
- knowledge deficit 
3. Patient and or family 
caregiver inability to 
recognize symptoms – 
knowledge deficit 
4. Passive attitude towards 
diagnosis 
5. Difficulty with 
assessment 
6. Lack of knowledge of 
tools to assist with 
assessment 
1. Healthcare team 
education – DIPS 
assessment & treatment 
algorithm 
2. After pilot with 
Neurology & changes 
made based on what 
learned, will roll out with 
Neurosurgery 
3. Share data for feedback 
4. Focus group interviews 
5. Ask “what – who – when 
– outcome” 
Initial State Solution Approach Confirmed State 
1. Up to 55% exhibited any 
depression symptoms 
during admission with as 
high as 28% exhibiting 
major depression 
symptoms 
2. 58% screened 
3. Of those with major 
depression symptoms, 
less than 30% were 
treated  
1. Utilize EBQA to 
implement DIPS project 
1. Monthly tracking of 
outcome measures 
 
Target State Rapid Experiments Insights 
1. 85% screened 
2. Of those scoring positive 
for PSD, 85% 
documentation of 
treatment & follow-up 
plan 
1. Patients admitted to 
neurology service 
2. Evaluate who needs to be 
involved for success 
(nursing, physicians, 
ancillary staff, NP) 
3. Evaluate nursing use of 
screening tool and 
medical team use of DIPS 
algorithm for treatment 
during admission 
1. At the end of the project 
will evaluate lessons 
learned 
2. Evaluate needed changes 
3. Was the project 
successful and in what 
form should the program 
continue? 
4. What failures were 
associated with the 
project? 
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Set Priorities (Plan): 
In order to implement the project, a core DIPS team was engaged to promote the plan. 
The DIPS team consisted of nursing and physician leadership from the neuroscience service line, 
process champions from key stakeholder groups (nurses from 6 neuroscience hospital (6NSH) 
and neurology stroke fellow) and a stroke survivor. The team reviewed literature and data 
collected from phase one of the project (patients enrolled to determine prevalence of PSD in 
UNC HealthCare patients) addressing the importance of detecting and treating PSD to garner 
buy-in and compliance. The stroke survivor shared their own personal UNC experience, 
identifying the need for DIPS. Focus groups with key stakeholders provided knowledge on 
barriers to assessing and treating PSD and resulted in a strategized approach for incorporating 
DIPS into routine care. The project leader facilitated the team in developing a concept map 
(Appendix 5) and provided training on DIPS.  
Set Guidelines (Do): 
The most impactful change with implementing DIPS was a standardized assessment and 
treatment algorithm (Appendix 6) with increased adherence to best practice recommendations. 
DIPS standardized roles using current staff, integrated the care team and provided patient-
centered care with no increased costs. Implementation of the project occurred in phases, 
beginning with the neurology service line, making changes based on data collection prior to 
implementation with neurosurgery. The Core team educated staff, functioning as a direct line of 
communication. 
Measure Performance (Study): 
The collection of process metrics and direct feedback occurred prior, during and after 
project implementation to evaluate success and failures. Project evaluation consisted of monthly 
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staff reports on performance indicators, collected by the study principal investigator (PI) and 
stroke data analyst through retrospective chart reviews and continuous feedback from informal 
stakeholder interviews.    
Improve Performance (Act): 
After study completion, the core team will determine how to implement the next cycle of 
the DIPS project. Information learned from the neurology phase will be incorporated to improve 
the process prior to implementation of the neurosurgery phase.   
Healthcare Worker Engagement 
Ensuring healthcare team buy-in is complex and often requires multiple levels of 
interventions. The DIPS program utilized approaches that target professionalism, education and 
the spirit of academia. Strategies included:  
• Face-to-face education – by peers, stroke fellow or NP, grand rounds, resident 
lectures, journal club, nursing staff meetings 
• Reminders through huddles, postings at bedside and computer, conference room 
educational bulletin board, via patient electronic health record (EHR) audit and 
feedback (monthly data report) 
• Bottom-up motivation – residents, nurses, pharmacist, champions, stroke research 
team, stroke coordinators 
• Use of evidence based guidelines – knowledge and best practice guidelines shared 
through grand rounds, resident lectures, nursing virtual library and face-to-face 
• Small group needs assessment – adapt change to team needs in stepwise approach 
• Listen to feedback and adapt – physician and nurse roundtable discussions 
• Engage stroke survivor and stroke advisory board - show impact of care 
 
Organizational coherence is an important element to quality improvement efforts 
focusing on three key elements: people, process and perspectives. This project utilized a 
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conceptual model of organizational coherence to reduce confusion and resistance, thereby 
improving engagement of staff (McAlearney, et al., 2013). The three areas of focus included:  
1. Social system coherence – improves understanding of individual roles  
Several members of the core DIPS team completed yellow belt training, as well as 
project training to establish individual roles and responsibilities for improved success. 
2. Intra-organizational coherence – consistent process across the unit and departments 
6NSH nurses and neurology physicians received training to ensure that the 
process was consistently incorporated into assessments and care of the stroke patient. 
Input from the unit-level, specifically the nurses and residents was key to develop the 
educational program. The “ground up” level input improved the success of staff buy in 
for the project. Nursing leaders were project champions for the unit nursing staff, while 
the stroke fellow and stroke-attending physician represented the resident physicians. 
Standard patient stroke education incorporated PSD education with the stroke survivor 
providing mentoring support. 
3. Coherent process – consistency to achieve goals and align with mission 
The core team aligned project goals with the mission of the Stroke Center, thereby 
facilitating efforts to meet patient needs and provide high quality patient-centered care. 
Incorporation of neuroscience, nursing and physician leadership aided with success and 
sustainability. The neurology department provided support. 
Study Design 
 DIPS utilized a prospective observational study design with a convenience sample to 
answer the project research questions. Approval by the University of North Carolina Medical 
Institutional Review Board (IRB) was obtained prior to study initiation for both phase-one, 
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population evaluation, (Appendix 7) and phase-two, evidence-based practice change, (Appendix 
10). Both studies had IRB approved consent forms (Appendix 8 and 11) and Health Insurance 
Portability and Accountability Act forms (HIPAA’s, Appendix 9 and 12).  
Setting 
 The project took place at UNC Healthcare on 6-Neuroscience Hospital, a 32-bed acute 
care floor that houses the neurology service. The Department of Neurology provided a letter of 
support (Appendix 13) with project implementation starting on March 28, 2017. 
 Study Population and Recruitment 
This study occurred in two-phases. Phase one determined depression prevalence and 
incidence in the stroke population treated at UNC HealthCare. The sample included 271 
ischemic (IS) hemorrhagic stroke (ICH), subarachnoid stroke (SAH) and transient ischemic 
attack (TIA) patients admitted to UNC HealthCare Neurology service between July 18, 2014 and 
January 24, 2017 that met inclusion criteria and agreed to participate with follow-up for six 
months. Based on the total yearly population of 950 stroke patients, 5% margin of error, and 
95% confidence level, the sample size calculated at 274 subjects. 
Phase two. The DIPS study evaluated a process improvement project. The sample 
included 85 IS, ICH, SAH and TIA patients admitted to UNC HealthCare neurology service 
between March 28 and August 8, 2017 that met inclusion criteria and agreed to participate with 
follow-up for 30 days. The neurology service primarily treats IS, ICH and TIA with some 
overlap with neurosurgery and the neurosurgery service treats SAH solely. Although SAH 
patients receive treatment by the neurosurgery service, nurses on the 6NSH acute care floor 
provide care to all stroke patients regardless of categorization. Based on the total yearly 
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population of 950 stroke patients, 10% margin of error, and 95% confidence level, the sample 
size calculated at 87 subjects.  
 Inclusion criteria for both samples included: (1) diagnosis of stroke, (2) age > 18, (3) able 
to obtain consent (may use legally authorized representative) and (4) able to speak English or 
Spanish. Exclusion criteria included: (1) non-stroke admission, (2) age < 18, (3) severity of 
illness preventing participation during admission, such as severe cognitive impairment, comfort 
care and (4) non-English or Spanish speaking. The study team evaluated patients based on ability 
to answer or point to responses on the questionnaires; thus, aphasia was not an absolute 
exclusion.  
The stroke research team remained aware of all patients admitted to UNC Healthcare 
with a diagnosis of stroke/TIA through the limited waiver of HIPAA for study screening 
purposes. In addition, the stroke NP had access to the daily list of stroke patients for continuity 
of care. Recruitment of patients and their family/caregiver occurred during admission to UNC 
HealthCare on the 6NSH acute care floor or in the neuroscience intensive care unit (NSICU). To 
maintain privacy, the study team conducted the consent process in the patient’s room. The team 
made every effort to ensure that the patient’s family member/caregiver was present during the 
consenting process.   
Consent Procedures 
 During admission to UNC HealthCare, the patient and family/caregiver were approached 
about participating in the study. The team explained the study, reviewed the consent form and 
allowed time for questions. After a stroke, the patient may be unable to verbalize due to aphasia 
or experience cognitive deficits. If necessary, the study team explained the study to the legally 
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authorized representative (LAR) in order to obtain consent. No deviations from the UNC IRB 
standard operating procedures for LAR consenting process occurred.  
Subject Costs and Compensation 
 Patients participating in this study incurred no financial costs and received no 
compensation.                                                                                                                                                                                                                                                                                     
Benefits/Risks     
 This project will help the UNC Stroke Center improve its current process of identifying 
and treating depression in the stroke population admitted to UNC HealthCare. Studies have 
shown that depression is associated with poor recovery of activities of daily living and a higher 
mortality rate as well as longer hospital admissions (McIntosh, 2017).  Husaini, et al. (2013) 
reported a significant increase in hospital costs in depressed stroke patients compared to non-
depressed ($77,864 versus $47,790, p < 0.001).  Early identification and treatment of PSD 
predicted improvement in functional outcomes and decreased hospital costs (Husaini, et al., 
2013). 
 It is common for stroke patients to experience some emotional distress and/or 
embarrassment regardless of study participation. A stroke may cause devastating injuries, 
leading to emotional distress, which may take a period of adjustment. A patient may become 
upset when asked about their functional status and mood after the stroke. The study team 
understood the physical and emotional changes associated with stroke and therefore 
demonstrated patience, compassion and comfort. In addition, staff were aware of referral 
resources within the hospital to help the patient and family/caregiver cope. Communication with 
the PCP regarding changes in the PHQ-9 score occurred upon discharge and at each follow-up 
visit as necessary.  
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 The study team and the stroke NP followed patients for one month after discharge 
through phone calls at day 7 and day 30. If the PHQ-9 increased from baseline and/or the patient 
experienced side effects to prescribed antidepressants, the stroke NP made medication 
adjustments as needed and notified the patient’s PCP. If a patient scored positive (> 1) on 
question 9, assessment for suicidal ideation ensued. Referral to a mental health professional or 
law enforcement would have occurred based on the NP assessment. Example questions the NP 
may ask included: 
1. Do you have thoughts about ending your life?  If so, how often do you have these 
thoughts?  When did the thoughts begin? 
 
2. Did you have stressors/event that caused you to have thoughts of ending your life? 
3. Have you devised a plan to end your life?  If so, what is your plan? 
4. Do you have the means/items with you to carry out your plan?  Where are they right 
now? 
 
5. What have you done to begin to carry out your plan? 
6. What would it accomplish to end your life?  
7. Have you ever tried to end your life in the past?  If so, when did you try this?  How 
did you try to end your life?  What was the outcome? 
   
8. Do you want to avoid ending your life? 
 
In order to minimize the risk of loss of confidentiality, case report forms (CRFs) were de-
identified (patients were assigned a number) and kept in a locked office building, that is 
employee badge protected. The key to the de-identified CRF is stored on a secure server 
protected by the University and password credentials.  
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Data Maintenance and Security 
 Data collection using the patient’s medical record and personal information provided by 
the patient and/or family/caregiver occurred at each study time point. For data security, all 
subjects received an identifier to de-identifying the data. Study materials were stored in a locked 
office requiring badge authorization for access. Data transmission occurred in person, through 
original hard copies of source documents, or through notes in EPIC. Study coordinators and 
investigators collected data points and recorded them on CRFs. De-identified data, entered into 
the DIPS database, was housed on a secure server, maintained and secured by the University. 
Access to the study data occurred using password credentials.  
Study Procedures 
Following consent, subjects will complete a 30-day observational period. The schedule of 
activities outlines information collected and procedures performed during the study (Appendix 
14). 
Study Specific Documents   
 The protocol included use of the mRS (Appendix 15) to determine pre-and post-stroke 
functional ability and NIHSS (Appendix 16) to assess patients, determining stroke severity. The 
PHQ-9 assessment tool (Appendix 17) evaluated patients for depression and administered to the 
family/caregiver as patient-proxy (Kroenke, Spitzer & Williams, 2001). Documentation of the 
mRS, NIHSS and PHQ-9 in the patient’s electronic medical record ensured continuity of care. 
Development of case report forms (CRF) (Appendix 18) allowed collection of study variables 
and efficient documentation into the PSD study database. Neurology information technology (IT) 
support utilized File Maker Pro to create the DIPS database under the guidance of the principal 
investigator. Following the DIPS treatment algorithm (Appendix 6) and recommended 
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medication chart (Appendix 19), the neurology resident documented the PHQ-9 score and 
treatment plan in the EHR. A letter for the patient’s primary care provider (PCP) was available 
explaining the study, PHQ-9 and treatment recommendations (Appendix 20). The PCP received 
the letter if the patient scored in the depression category on the PHQ-9 and/or if there were 
changes in the score, indicating depression or worsening of symptoms. Measurement of staff 
satisfaction occurred through use of an investigator developed online questionnaire (Appendix 
21 and 22), designed to measure knowledge of PSD and satisfaction with implementation of the 
DIPS project. 
Outcome Measures 
The primary outcome was utilization of the PHQ-9 screening assessment tool by nursing 
staff with a target utilization of 85%. Since screening is part of the standard of care, education 
focused on the transition from the PHQ-2 to the PHQ-9. Creation of a research tab to house the 
PHQ-9 simplified documentation. A second primary outcome was utilization of the DIPS 
algorithm and development of a treatment plan by the neurology residents, with a target 
documentation rate of 85%. For purposes of this study, development of a treatment plan was 
positive if the resident documented an antidepressant was prescribed or reasons for not 
prescribing. To support resident documentation, a templated section for DIPS supplemented the 
discharge summary. The third primary outcome was to improve the depression treatment rate 
from 28.7%, identified in the phase-one study sample. Secondary outcomes included (1) 
assessment of the association between depression symptoms and functional status, (2) determine 
if a correlation between patient reported PHQ-9 and proxy reported PHQ-9 results at admission, 
discharge days seven and 30 exist (3) identify if a difference exist due to completion timing of 
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the PHQ-9 by the patient during admission and (4) assess staff satisfaction with project 
implementation.  
Data Analysis 
  Statistical analysis utilized SAS for windows version 9.4. Bivariate relationships 
between two continuous variables were examined using Pearson’s correlation; between a 
dichotomous or ranked variable and a continuous variable were examined using Spearman’s 
correlation, and between two dichotomous variables using Phi coefficient. Frequency data 
including prevalence and incidence were examined using Chi square (X2). A dependent t-test 
compared time of administration between PHQ-9 responses during admission. Analysis of 
Variance (ANOVA) evaluated the difference in continuous variables between the PSD positive 
and PSD negative groups. For this study, a p-value of < 0.05 (two-tailed) presumes significance. 
Descriptive statistics were used to analyze staff satisfaction with project implementation.  
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CHAPTER 5: DATA ANALYSIS 
Sample Characteristics and Response Rate 
The phase-two DIPS sample (Table 5.1) included 85 patients of whom 41 (48.24%) were 
male and 44 (51.76%) were female. The group’s racial identity was primarily white (58.82%) 
and black (34.12%) with low representation among Hispanic (4.71%) and Asian (2.35%) groups. 
The mean age was 65.5 (age range 25 to 96). Ischemic stroke represented the largest group 
(n=68, 80%) followed by ICH (n=15, 17.65%), TIA (n=1, 1.18%) and SAH (n=1, 1.18%).  
16.47% (n=14) did not graduate from high school, 34.12% (n=29) held a high school diploma or 
general education diploma (GED), 28.4% (n=24) reported completing some college, 10.59% 
(n=9) completed an undergraduate degree and 10.59% (n=9) completed graduate, including 
masters and doctoral degrees. Work history prior to admission included: (1) nine (10.59%) 
disabled, (2) 20 (23.53%) working full-time, (3) four (4.71%) identifying as a homemaker, (4) 
four (4.71%) working part-time, (5) 42 (49.41%) retired, (6) one (1.18%) as a student and (7) 
five (5.88%) unemployed.  
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Table 5.1: Phase-Two DIPS Sample (n=85): Demographics of the Participants 
Variable Total (n=85) Depressed % Non-Depressed % p-value 
SEX    P = 0.57 
Female 44 22 (50%) 22 (50%)  
Male 41 18 (43.9%) 23 (56.1%)  
AGE    P = 0.89 
18-45 7 4 (57.1%) 3 (42.9%)  
46-65 32 16 (50%) 16 (50%)  
66-85 39 17 (43.6%) 22 (46.4%)  
 > 86 7 3 (42.9%) 4 (57.1%)  
RACE    P = 0.27 
Black 29 12 (41.4%) 17 (58.6%)  
Caucasian 50 23 (46%) 27 (54%)  
Hispanic 4 3 (75%) 1 (25%)  
Asian 2 2 (100%) 0  
STROKE SUB-TYPE    P = 0.26 
ICH 15 4 (26.7%) 11 (73.3%)  
IS 68 12 (17.6%) 56 (82.4%)  
SAH 1 1 (100%) 0  
TIA 1 0 1 (100%)  
EDUCATION    P = 0.53 
Not High School Graduate 14 9 (64.3%) 5 (35.7%)  
High School Graduate 29 13 (44.8%) 16 (55.2%)  
Some College 24 12 (50%) 12 (50%)  
Under Graduate College 
Degree 
9 3 (33.3%) 6 (66.7%)  
Graduate Degree 9 3 (33.3%) 6 (66.7%)  
WORK HISTORY    P = 0.08 
Disabled 9 7 (77.8%) 2 (22.2%)  
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Full-Time 20 7 (35%) 13 (65%)  
Part-time 4 1 (25%) 3 (75%)  
Homemaker 4 4 (100%) 0  
Retired 42 18 (42.9%) 24 (57.1%)  
Student 1 0  1 (100%)  
Unemployed 5 3 (60%) 2 (40%)  
PLACE of DISCHARGE    P = 0.59 
Home 59 26 (44.1%) 33 (55.9%)  
Acute Inpatient 
Rehabilitation 
18 9 (50%) 9 (50%)  
Skilled Nursing Facility 8 5 (62.5%) 3 (37.5%)  
 
 
Regarding comorbid conditions present prior to stroke onset, the phase-two DIPS sample 
experienced a wide range of illness, chief among these were hypertension, diabetes, 
hyperlipidemia and heart disease (Table 5.2).  
 
 
Table 5.2: Phase-Two DIPS Sample (n=85): Frequency of Associated Illnesses Prior to 
Admission (Past Medical History) 
 
MEDICAL HISTORY DIAGNOSIS PRESENT 
Depression 17 (20%) 
Anxiety 11 (12.94%) 
Prior Stroke/TIA 16 (18.82%) 
Hypertension 64 (75.29%) 
Diabetes 30 (35.29%) 
Hyperlipidemia 30 (35.29%) 
Atrial Fibrillation 8 (9.41%) 
Heart Disease 23 (27.06%) 
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Cancer 17 (20%) 
End-Stage Renal Disease 4 (4.71%) 
Obstructive Sleep Apnea 5 (5.88%) 
Obesity 5 (5.88%) 
Tobacco Use 15 (17.65%) 
Alcohol Abuse 3 (3.53%) 
Substance Abuse 8 (9.41%) 
 
The phase-one sample (n=271) was demographically very similar to the DIPS sample (Table 5.3 
and Table 5.4). 
 
Table 5.3: Phase-One Sample (n=271): Demographics of Participants 
Variable Total (n=271) Depressed % Non-
Depressed % 
p-value  
 SEX        P = 0.71 
    Female  125 (46.1%)  61 (48.8%)  64 (51.2%)   
    Male  146 (53.9%)  68 (46.6%)  78 (53.4%)   
 AGE        P = 0.56 
    18-45  39 (14.4%)  20 (51.3%)  19 (48.7%)   
    46-65  118 (43.5%)  63 (53.4%)  55 (46.6%)   
    66-85  94 (34.7%)  38 (40.4%)  56 (59.6%)   
   > 86  20 (7.4%)  8 (40%)  12 (60%)   
 RACE        P = 0.67 
 Black  95 (35.1%)  50 (52.6%)  45 (47.4%)   
 Caucasian  162 (59.8%)  73 (45.1%)  89 (54.9%)   
 Hispanic  9 (3.3%)  4 (44.4%)  5 (55.6%)   
 Other  5 (1.8%)  2 (40%)  3 (60%)   
Stroke Sub-type    P = 0.46 
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Intracerebral Hemorrhage 
(ICH) 
47 (17.3%) 22 (46.8%) 25 (53.2%)  
Ischemic (IS) 163 (60.1%) 78 (47.85%) 85 (52.15%)  
Subarachnoid Hemorrhage 
(SAH) 
40 (14.8%) 22 (55%) 18 (45%)  
Transient Ischemic Attack 
(TIA) 
21 (7.7%) 7 (33.3%) 14 (66.7%)  
Place of Discharge    P = 0.055 
Home 190 (70.1%) 84 (44.2%) 106 (55.8%)  
Acute Inpatient 
Rehabilitation 
63 (23.3%) 33 (52.4%) 30 (47.6%)  
Skilled Nursing Facility 18 (6.6%) 13 (72.2%) 5 (27.8%)  
 
Table 5.4: Phase-One Sample (n=271): Frequency of Associated Illnesses Prior to Admission 
(Past Medical History)  
 
Medical history Diagnosis Present 
Depression 31 (11.4%) 
Anxiety 15 (5.5%) 
Prior CVA 63 (23.25%) 
Hypertension 186 (68.6%) 
Diabetes 72 (26.6%) 
Hyperlipidemia 106 (39.1%) 
Atrial Fibrillation 27 (9.96%) 
Heart Disease 54 (19.9%) 
Cancer 24 (8.9%) 
Tobacco Use 58 (21.5%) 
Alcohol Abuse 9 (3.3%) 
Substance Use 13 (4.8%) 
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The total dropout rate by day 30 was 3.5% (n=3) based on the inability to locate patients via 
telephone follow-up for at least three attempts (n=1), hospitalization (n=1), or hospice/death 
(n=1).  
Depression Symptom Prevalence on Admission, Discharge Day 7 and Discharge Day 30 
Admission 
 Of the 85 subjects enrolled, 17 (20%) had a previous history of depression. Forty 
(47.06%) subjects reported symptoms of depression during admission (Figure 5.1) with no 
statistically significant differences between groups (IS, ICH, SAH and TIA) (p=0.26). Twenty-
one (24.71%, p=0.68) reported moderate to severe depression symptoms while 19 (22.35%, 
p=0.56) experienced minor depression symptoms. Of these 40 subjects with depression during 
admission, 14 (35%) reported a prior history of depression.   
Discharge Day 7 
At discharge day 7, 39 (46.43%, p=0.0007) total subjects reported depression symptoms 
(Figure 5.1). Of the 45 non-depressed patients reporting no depression symptoms during 
admission, 16 (35.56%) (p = 0.053) patients reported new symptoms of depression at discharge 
day 7, with one (2.22%) of those reporting moderate to severe depression symptoms (p=< 
0.0001) and 15 (33.33%) reporting minor symptoms (p = 0.0253). These results are slightly 
higher than the phase-one sample that found 24.7% new cases at day 7.  
Discharge Day 30 
At discharge day 30, thirty-seven (45.12%, p=0.0020) total subjects reported depression 
symptoms (Figure 5.1). At the day 30 assessment, of the 45 non-depressed patients from the 
admission period, 13 (28.89%) (p=0.0046) patients reported symptoms of depression with one 
(2.22%) of those reporting moderate to severe depression symptoms (p=< 0.0001) and 12 
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(26.67%) reporting minor symptoms (p = 0.0017). Of the 29 non-depressed patients from the day 
7 assessment, six (20.69%) patients reported new depression symptoms at day 30. This result is 
also slightly higher than the phase-one sample that found 11.2% new cases at day 30.  
 
Figure 5.1: Percent Depression Symptoms Reported During Admission, at Discharge Day 7 and 
at Discharge Day 30 
 
 
 
Documentation of PHQ-9 Screening by Nursing 
A retrospective chart review of all stroke patients, including those enrolled into the DIPS 
study, admitted to the neurology service examined rates of PHQ-9 documentation by nursing 
from April through August 2017. Implementation of the project generated a median 
documentation rate of 81% (Table 5.5). 
Documentation of Treatment Plan by Neurology Treatment Team 
A retrospective chart review of all stroke patients, including those enrolled into the DIPS 
study, admitted to the neurology service examined documentation rates of PHQ-9 scores and 
treatment plan by the treating physician from April through August 2017. Implementation of the 
project generated a median documentation rate of the treatment plan at 94% in the discharge 
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summary (Table 5.5). Although not part of the study guidelines, if the PHQ-9 was not completed 
by nursing, physicians contacted the study team to request an assessment. 
 
Table 5.5: Documentation rates for PHQ-9 scores by nursing and treatment plan based on PHQ-9 
score by physicians in the discharge summary 
 
 
Staff April May June July August Median 
Nursing 41% 
(n=39) 
69% 
(n=26) 
97%  
(n=30) 
81%  
(n=36) 
87%  
(n=31) 
81% 
Physicians 71% 
(n=39) 
69%  
(n=26) 
100%  
(n=30) 
94%  
(n=36) 
100%  
(n=31) 
94% 
 
Treatment Rate during Admission, at Discharge Day 7 and at Discharge Day 30 
During admission 
Of the total patients (n=40) reporting any depression symptoms, 15 (37.5%) were on 
treatment (p=0.0005) at the time of in-patient admission (Figure 5.2). When comparing patients, 
10 (47.62%, p=0.0006) patients reported moderate to severe depression and five (26.32%, 
p=0.0006) reported minor depression symptoms. An additional three patients were on 
antidepressants that denied depression symptoms as evidenced by a negative PHQ-9. Phase-two 
results are higher when compared to the phase-one sample where 28.7% received treatment 
during admission. 
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Figure 5.2: Pre-and Post-DIPS Intervention Treatment Rates: Admission, Discharge, Discharge 
Day 7 and Discharge Day 30  
 
 
 
Discharge 
At discharge, of the total patients (n=40) reporting depression symptoms, 16 (42.11, 
p=0.0002) were treated with antidepressants (Figure 5.2). Twelve (60%, p < 0.0001) had 
moderate to severe depression symptoms and four (22.2%, p < 0.0001) had minor depression 
symptoms. Out of the nine patients with moderate to severe depression symptoms not treated, 
discontinuation of antidepressants occurred in one patient due to concern for salt wasting and 
four patients refused when offered treatment. Out of the 15 with minor depression symptoms not 
treated, two patients refused treatment. An additional three patients were on antidepressants that 
denied depression symptoms, reported as a negative PHQ-9. 
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Ad Hoc Analysis: Project Effect on PSD Treatment among All Stroke Patients 
A retrospective chart review of all stroke patients, including those enrolled into the DIPS 
study, admitted to the neurology service, examined treatment rates at discharge of patients 
scoring in the minor (PHQ-9: 5-9) and moderate to severe (PHQ-9: > 10) category from April 
through August 2017 (Table 5.6). Compared to the treatment rate in the original sample (28.7%), 
over time a clinical improvement occurred. 
 
Table 5.6: Treatment Rates at Discharge for All Stroke Patients Scoring in the Minor (PHQ-9: 5-
9) and Moderate to Severe (PHQ-9: > 10) Category from April through August 2017 
 
 
Treatment Rates April May June July August 
Moderate to 
Severe Depression 
Symptoms  
(PHQ-9 = > 10) 
100% (2 
patients 
treated) 
(n=2) 
60% (3 
patients 
treated) 
(n=5) 
80% (4 
patients 
treated, 1 
refused) 
(n=5) 
80% (4 
patients 
treated, 1 
refused) 
(n=5) 
67% (4 
patients 
treated, 1 
refused) 
(n=6) 
Mild Depression 
Symptoms  
(PHQ-9 = 5-9) 
12.5% (1 
patient 
treated) 
(n=8) 
0 
(n=4) 
57% (4 
patients 
treated, 2 
refused) 
(n=7) 
60% (3 
patients 
treated, 1 
refused) 
(n=5) 
100% (3 
patients 
treated) 
(n=3) 
Total 30%  
(n=10) 
33%    
(n=9) 
66.7% 
(n=12) 
70%  
(n=10) 
77.78% 
(n=9) 
 
Discharge Day 7 
By discharge day seven, of the total patients (n=84) observed, 39 reported depression 
symptoms, 17 (43.59%, p=0.0007) were treated with antidepressants (Figure 5.2). There had 
been no change in the treatment rate for moderate to severe depression symptoms, 57.14%, 
p=0.0004. However, one additional patient with minor depression symptoms received treatment 
(n=5, 27.78%, p=0.0004). An additional five patients were on antidepressants that denied 
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depression symptoms, as evidenced by a negative PHQ-9. Comparatively, prior to project 
implementation, only 30.2% of the phase-one sample received treatment by discharge day 7. 
Discharge Day 30 
By discharge day 30, of the total patients (n=82) observed, 37 reported depression 
symptoms, 15 (40.54%, p=0.002) were treated with antidepressants (Figure 5.2). Ten (50%, p < 
0.0001) had moderate to severe depression symptoms and five (29.41%, p = 0.003) had minor 
depression symptoms. An additional five patients were on antidepressants that denied depression 
symptoms, as evidenced by a negative PHQ-9. Comparatively, prior to project implementation, 
only 29.7% of the original sample received treatment by discharge day 30. 
Association of PSD and Severity of Stroke and Functional Disability 
Documentation of pre-stroke modified Rankin (mRS) scores occurred on each patient 
upon admission and post-stroke mRS at the time of discharge. Eight of the 85 subjects (9.4%) 
were disabled prior to the stroke based on mRS of > 3.  Forty-one percent of subjects were 
categorized as having minor strokes (NIHSS score 1-4), followed by 29.41% as moderate strokes 
(NIHSS score 5-15). At discharge, 35 of the 85 (41.2%) were disabled, by day 7 after discharge, 
31 (36.5%) and by discharge day 30, 27 (31.8%) subjects reported continued disability. Of those 
with depression symptoms (n=40), 17 (42.5%) were disabled (p=0.28). An analysis of variance 
found that mean PHQ-9 scores were not significantly greater in the disabled group (M=6.9, 
SD=6.01) relative to those not disabled (M=5.3, SD=5.36), (F(1,83)=1.72, p=0.193). However, 
when the DIPS sample (n=85) was combined with the original sample (n=271) for a total sample 
n of 356, an analysis of variance found that mean PHQ-9 scores were significantly greater in the 
disabled group (M=7.1, SD=5.63) relative to those not disabled (M=5.4, SD=5.3), 
(F(1,354)=7.40, p=0.0068). This was also true for the phase-one sample (n=271). When 
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independently analyzed there was a significant difference (F(1,269)=5.66, p=0.018) in mean 
patient reported PHQ-9 scores between those disabled (M=7.1, SD=5.5) and those not disabled 
(M=5.5, SD=5.3). 
Although it was not statistically significant (p=0.595), this study found a higher report of 
any depression symptoms in patients discharged to a SNF. When compared by degree of 
symptomatology, there was no statistical significance between moderately to severe depression 
symptoms and discharge location (p=0.186), however, a significant association existed between 
minor depression symptoms and discharge location to a SNF (p=0.016). Combining the DIPS 
sample with the original sample found a statistically significant (p=0.018) report of any 
depression symptoms compared to no depression symptoms in patients discharged to a SNF 
(69.23% versus 30.77%) and to AIR (53.85% versus 46.15%) contrasted to those discharged 
home (56.75% versus 43.25%) (Table 5.7). Similar to the DIPS sample, the combined sample 
found complaint of moderate to severe depression symptoms not statistically significant 
(p=0.45), yet a significant association existed between minor depression symptoms and 
discharge location to a SNF (p=0.005).  
 
Table 5.7: Phase-One Sample plus DIPS Sample (n=356) Percent Depression Symptoms Based 
on Discharge Location, p=0.018 
   
DISCHARGE 
LOCATION 
TOTAL DEPRESSED NOT DEPRESSED 
HOME 252 (70.8%) 109 (43.25%) 143 (56.75%) 
ACUTE IN-
PATIENT 
REHABILITATION 
78 (21.9%) 42 (53.85%) 36 (46.15%) 
SKILLED NURSING 
FACILITY 
26 (7.3%) 18 (69.23%) 8 (30.77%) 
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Timing of PHQ-9 Assessments 
Of the 85 subjects enrolled into the study, 73 completed the PHQ-9 assessment at two 
different time points during admission. The patient completed the initial assessment with 
assistance of nursing and the second assessment with assistance by the stroke research team. The 
mean assessment time of completion for the initial assessment was 1.08 days from admission and 
2.23 days from admission to the second assessment. A dependent samples t-test compared PHQ-
9 on admission (visit 1) and PHQ-9 done later during admission (visit 2). There was a significant 
difference in scores from the initial PHQ-9 at visit 1 (M=4.59, SD=5.8) and the second PHQ-9 at 
visit 2 (M=6.16, SD=5.8); t (72) = -2.93, p = 0.0046.  
Caregiver Correlation 
 In order to assess use of a proxy, both caregivers and study subjects completed the PHQ-
9 at each study visit. Agreement between patient and caregiver as proxy was significant at 
admission, discharge day 7 and discharge day 30 (p < 0.0001). A moderately positive 
relationship between patient report of PHQ-9 and proxy report of PHQ-9 occurred at admission 
(re=0.494, p<0.0001, n=65), discharge day 7 (re=0.634, p<0.0001, n=71) and a strongly positive 
relationship at discharge day 30 (re=0.730, p<0.0001, n=70) (Table 5.8). When the two samples 
were combined, the relationship remained moderately positive at admission (re=0.492, p<0.0001, 
n=260), discharge day 7 (re=0.519, p<0.0001, n=254) and discharge day 30 (re=0.588, 
p<0.0001, n=261) (Table 5.9). 
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Table 5.8: Phase-Two DIPS Sample (n=85): Pearson’s Correlation between Patient PHQ-9 and 
Proxy PHQ-9 
 
 ADMIT PATIENT 
PHQ-9 
DAY 7 PATIENT 
PHQ-9 
DAY 30 PATIENT 
PHQ-9 
ADMIT PROXY 
PHQ-9 
0.49374   
 <0.0001   
 65   
DAY 7 PROXY 
PHQ-9 
 0.63412  
  <0.0001  
  71  
DAY 30 PROXY 
PHQ-9 
  0.73017 
   <0.0001 
   70 
 
 
Table 5.9: Phase-One Sample plus DIPS Sample (n=356) Pearson’s Correlation between Patient 
PHQ-9 and Proxy PHQ-9 
 
 ADMIT PATIENT 
PHQ-9 
DAY 7 PATIENT 
PHQ-9 
DAY 30 PATIENT 
PHQ-9 
ADMIT PROXY 
PHQ-9 
0.49187   
 <0.0001   
 260   
DAY 7 PROXY 
PHQ-9 
 0.51861  
  <0.0001  
  254  
DAY 30 PROXY 
PHQ-9 
  0.58788 
   <0.0001 
   261 
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Staff Satisfaction 
 Nursing staff and physicians received a seven-question survey (physician n=14 and nurse 
n=37) (Appendix 21 and 22). Twelve physicians and 16 nurses responded to the questionnaires 
with a total response rate of 54.9% (physician response rate = 85.7% and nurse response rate = 
43.2%) 
 
Depression Improvement Program in Stroke (DIPS) Physician Satisfaction Questionnaire 
 
Figure 5.3: Question #1: Do You Believe Many of Your Stroke Patients Need Help with 
Depression? 
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Figure 5.4: Question #2: Did You Receive Education/Information About PSD and the 
Importance of Treatment for Depression Symptoms in Stroke Patients? 
 
 
 
 
Figure 5.5: Question #3: Do You Explain PSD to Your Patients/Families? 
 
 
 
 
0 2 4 6 8 10 12
Not Sure
No
Yes
0 1 2 3 4 5 6
Sometimes
No
Yes
50 
 
 
Figure 5.6: Question #4: Do You Understand How to Implement Treatment for PSD Based on 
the PHQ-9 Score? 
 
 
 
Figure 5.7: Question #5: Do You Know How to Find the PHQ-9 Score within EPIC? 
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Question # 6: What Went Well with the Implementation of DIPS Program? 
 Themes of physician comments to question six included (1) increased awareness and 
standardization of PSD care and (2) increased detection by nursing and physicians (Appendix 
23).  
Question #7: What Could Be Improved with the PHQ-9 Assessment/Documentation 
Process? 
 
Themes of physician comments to question seven included (1) continue to improve 
documentation of PSD response in electronic medical record and (2) continue education and 
training (Appendix 23).  
 
Depression Improvement Program in Stroke Program (DIPS) Nursing Satisfaction Questionnaire 
 
Figure 5.8: Question #1: Do You Believe Many of Your Stroke Patients Need Help with 
Depression? 
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Figure 5.9: Question #2: Did You Receive Education/Information About PSD and the 
Importance of Screening for Depression Symptoms in Stroke Patients? 
 
 
 
Figure 5.10: Question #3: Do You Explain PSD to Your Patients/Families? 
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Figure 5.11: Question #4: Since Implementation of the Depression Improvement Program 
in Stroke (Nurses Screening Using the PHQ-9 and Physicians Considering Treatment 
Based on The Score), Is There More Focus From the Physician Team on PSD? 
 
 
 
Figure 5.12: Question #5: Do You Report Off the PHQ-9 Score During Shift Report? 
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Question #6: What Barriers Do You Face in Assessing Your Stroke Patients for 
Depression? 
 
Themes of nursing comments to question six included (1) patient deficits such as 
cognitive impairment or aphasia and (2) family unable to answer questions (Appendix 24).  
 
Question #7: What Went Well with the Implementation of DIPS Program? 
Themes of nursing comments to question seven included (1) increased awareness, (2) 
effective PSD education and (3) ease of use in electronic medical record (Appendix 24).  
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CHAPTER 6: DISCUSSION 
This DNP project focused on the Doctoral Education Essential III by determining a need 
for change, critically evaluating the literature, designing a practice change, implementing and 
evaluating the quality improvement program (AACN, 2006). The primary goal of DIPS was to 
improve depression identification and treatment in stroke patients admitted to UNC Health Care 
in response to identifying a high rate of depression symptoms and a low treatment rate among 
hospitalized patients. Secondary outcomes measured included: (1) compare the relationship 
between PSD, severity of stroke, functional status and discharge location, (2) examine the effects 
of timing on screening, (3) evaluate if there is a correlation between the patient and caregiver as 
proxy responders to the PHQ-9 and (4) assess staff satisfaction with program process and 
implementation.  
 The literature reports PSD prevalence rates of approximately 33%, however these studies 
may not accurately reflect prevalence during the acute hospitalization phase due to the exclusion 
of hemorrhagic strokes, aphasic patients and combining hospital and acute rehabilitation settings 
(Robinson and Spalletta, 2010). Compared to the original sample enrolled from UNC Health 
Care, this study confirmed the high prevalence of reported depression symptoms during 
admission. Consistent with the literature (Towfighi, et al., 2016) and the phase-one sample, this 
study found no statistical differences between sex, age, or race. Additionally, this study found no 
association with PSD and education or work history.  
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Primary Outcome #1: Improve Documentation of PHQ-9 Screening by Nursing 
Prior to project implementation, nursing screened patients approximately 58% of new 
admissions using the PHQ-2. This was problematic for three reasons: (1) the low screening rate, 
(2) use of the PHQ-2 did not aid physicians in determining a treatment plan and (3) physicians 
were generally not aware of the screening results because these data were not verbally 
communicated and documentation within the EHR was difficult to find. Implementation of the 
project in April generated a median PHQ-9 documentation rate of 81% from April through 
August 2017. Although it did not reach the 85% goal set for the project, significant clinical 
outcomes were evident as demonstrated by improved treatment rates.  
 The most influential barrier to nursing documentation was the EHR. Specific stroke 
documentation flowsheets, known as tabs, are available within the EHR to facilitate 
documentation, continuity of care and quality improvement. Because UNC Healthcare is part of 
a network of hospitals, it is impossible to make changes to the EHR without approval from all 
network hospitals. Approval and modification of the EHR is a six-month process.  
Until approval of the PHQ-9 location in the nursing stroke template, nurses tried to use a 
smart phrase that inserted the PHQ-9 text into the note, for documentation. This first EHR work 
around was developed during focus group meetings with nursing and implemented in April. 
Although there was an improvement in documentation (41% to 69%), the nurses voiced 
annoyance with using the smart phrase. A second focus group meeting occurred with nursing 
leadership, the stroke center manager and identified nurse champions. Acting as change 
facilitators, the focus group developed the stroke research tab to overcome deficiencies of HER 
documentation. The research tab, created by nursing informatics within two weeks, is a separate 
link to documentation that nurses are able to pull into their main documentation screen and is 
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present each time they log in. Once available in the EHR, the nurses received education about 
completing the stroke research tab from members of the focus group, including the stroke NP, 
nurse leadership, and stroke center manager. Although the research tab added an additional 
documentation step for nursing, rates of PHQ-9 documentation improved. More importantly, the 
nurses voiced satisfaction with the research tab. McAlearney, et al., (2013) found within a team 
or unit, such as 6NSH, a coherence between individuals increases understanding of roles, 
responsibilities and leads to goal achievement. Engaging the nurses and physicians in building 
the process and making changes based on early feedback, increased shared understanding, 
commitment and improved project goal outcomes.  
Primary Outcome #2: Documentation of Treatment Plan by Neurology Treatment Team 
Prior to project implementation, physicians did not document patient’s depression 
screening results or treatment plan in either their progress notes or their discharge summary. 
After a grand rounds presentation on PSD, the neurology physicians declared the PHQ-9 score as 
the “sixth vital sign” for stroke care, and agreed to use the data in determining a treatment plan 
for PSD. Utilization of a smart phrase allowed the physician to pull the PHQ-9 score into their 
progress notes. Four strategies supported physician compliance with documentation: (1) peer led 
education sessions, (2) a treatment algorithm for quick reference on cell phones and posted in the 
physician workroom, (3) ease of documentation through a templated section for DIPS in the 
discharge summary and (4) attending physician support increased documentation rates. These 
efforts resulted in a significant increase in PSD symptom and treatment documentation rates.  
As with nursing, physicians valued the process improvement effort and expressed 
understanding of the need and logic behind the practice change. Sharing best practice through 
review of the literature at grand rounds and journal club meetings resulted in increased physician 
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knowledge and support. This level of coherence, deemed social system coherence, (McAlearney, 
et al., 2013) facilitated consistent action by the physicians surpassing the goal of 85% set at the 
beginning of the project.   
Primary Outcome #3: Improve Treatment Rates 
An important primary outcome was improvement of the treatment rate from 21.4%, 
identified in the phase-one study sample. This outcome was evaluated through data collected on 
subjects enrolled into the DIPS study and all stroke patients admitted to the neurology service 
between April and August 2017. The DIPS study sample revealed an improvement in the 
treatment rate at discharge from 21% to 42% but more importantly improved treatment in 
moderate to severe depression symptoms from 38% to 57%.  In the overall stroke population, 
admitted between April and August, the treatment rate of reported any depression symptoms 
improved from 30% to 78%.   
No treatment goal was set, as this depends on the individual needs of the patient. The 
study team did not want the physicians to provide a “cookbook” response to the PHQ-9, but to 
utilize a patient-centered approach, by further evaluating patient needs as identified by the PHQ-
9 screening. A unique benefit to the neurology treatment team was easy access to psychiatry 
residents. Often when the PHQ-9 returned in the moderate to severe range, the psychiatry 
resident assisted with evaluation and provided further treatment recommendations. The 
psychiatry resident added further social system coherence through their support and validation of 
the importance of the project aims.  
Although there is a consensus that treating PSD is appropriate, the right therapy and 
optimal time of screening continues to be determined (Towfighi, 2016). Yet, the FLAME trial 
provided encouraging results demonstrating that early treatment with fluoxetine and 
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rehabilitation therapy improves recovery in patients with ischemic stroke (Chollet, et al., 2011) 
and these results sparked three large European trials (FOCUS, AFFINITY and EFFECTS) 
examining treatment of PSD (Mead, et al., 2015). The FLAME trial also supports the theoretical 
framework, DFSSS, through examination of SSRIs effects on improved level of function.   
The findings of this study revealed that use of an evidence-based protocol improves 
treatment of PSD. Patients screening positive (> 5) on the PHQ-9 were more likely to receive 
treatment after implementation of the DIPS protocol. The DIPS protocol resulted in an improved 
standard of care for stroke patients reporting depression symptoms.  
Secondary Outcome #1: Is There a Correlation between PSD and Disability 
Correlation between stroke severity and associated functional disability has emerged as a 
predictor of PSD (Towfighi, et al., 2016) and discharge location (Zhang, Yang, & Saver, 2015). 
Additionally, PSD increases the risk of being prematurely institutionalized (Nuyen, et al., 2008). 
Nguyen, et al. (2007) examined 326 stroke survivors and found a FIM score of < 75 at admission 
predicted discharge to SNF and when combined with PSD led to limited recovery (Karaahmet, et 
al., 2017).  
 The DIPS sample did not show a significant association with disability and reported PSD 
symptoms. This discrepancy with the literature may be related to the small sample size and/or the 
higher enrollment of subjects with mild strokes. However, the combination of the DIPS sample 
with the original sample (n=356), found a significant association with disability and reported 
depression symptoms at discharge. In the combined sample, patients discharged to a SNF 
(69.23%) reported higher rates of any depression symptoms than those admitted to AIR 
(53.85%) or home (43.25%). Surprisingly, in both the DIPS sample and the combined sample, 
subjects reporting minor symptoms were significantly more likely to be discharged to a SNF and 
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less likely of discharged home. This suggests that a patient discharged to a SNF is more likely to 
be depressed and a potential risk factor for developing PSD. In addition, patients reporting minor 
symptoms are at higher risk of developing moderate to severe symptoms over time.  
Secondary Outcome #2: Timing of PHQ-9 Assessments 
These results suggest there was a significant increase in report of depression symptoms 
between visit 1 and visit 2. Currently the optimal time to screen for PSD is unknown (Towfighi, 
et al., 2016). Karamchandani, et al., 2015 found the PHQ-9 feasible for use during acute 
hospitalization. Yet, the question of appropriate timing during acute hospitalization remains. 
Should screening occur at admission or closer to discharge? Some clinicians argue that screening 
early during the acute phase of hospitalization will only capture the immediate reaction to acute 
hospitalization/new stroke diagnosis instead of reflecting a true depression syndrome 
(Karamchandani, et al., 2015). The biopsychosocial model of PSD describes early onset of PSD 
during the acute phase associated with interruption of neuronal circuits and depression symptoms 
continuing over time or developing later-onset of depression during the post-acute phase 
associated with functional deficits (Mast and Vedrody, 2006). The increase in reported 
depression symptoms over the two days of admission demonstrate a possible link to physical 
limitations affecting activities of daily living and/or the realization of life altering deficits. 
Secondary Outcome #3: Caregiver Correlation 
Among stroke patients, aphasia and cognitive disability may interfere with the ability to 
complete the PHQ-9 therefore; providers may need to rely on caregiver assessment. This study 
found moderately positive correlation between patient and proxy PHQ-9 scores, which may be 
due to the higher prevalence of patients reporting minor symptoms. Skolarus et al., (2010) found 
that median patient PHQ-9 scores compared to proxy were six versus five respectively 
demonstrating fair agreement based on an intra-class correlation coefficient of 0.41. The gap 
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between scores widened in light of lower levels of depression responses (Skolarus, et al., 2010). 
Similarly, Williams, et al. (2006) reported greater agreement between patients and proxy in 
patients with higher PHQ-9 scores and lower caregiver burden perception. Since the current 
study did not measure caregiver burden, this factor may need to be considered in future work.  
Secondary Outcome #4: Staff Satisfaction 
Staff nurses and physicians provided feedback on the DIPS project implementation useful 
for determining success and identifying areas for improvement. The goal of the questionnaires 
were to obtain knowledge on staff perception of PSD and gage project execution efficiency. One 
hundred percent of both physician and nurse respondents felt PSD was an important side effect 
of stroke requiring attention from the health care team. The majority of respondents received 
PSD education. Although a majority of physicians felt comfortable with the DIPS algorithm and 
treatment recommendations, the majority sometimes or did not discuss PSD with their patients. 
However, the majority of nurses responded that they did discuss PSD with their patients. 
Surprisingly, the survey identified that the majority of nurses were not sure or did not feel the 
physicians were concerned with PSD and do not share the PHQ-9 score during shift change 
report. The surveys revealed that ongoing education is needed and additional strategies to share 
data highlighting staff engagement and patient outcome successes. Respondents identified 
improvements to documentation within the electronic medical record as project barriers, which 
will be a focus prior to implementation of phase three on the neurosurgery service.  Additional 
barriers included difficulty with assessing aphasic and cognitively impaired patients. A reliable 
way to screen stroke patients with aphasia or comprehensive deficits is not currently available 
(Robinson and Spalletta, 2010) therefore; proxy responses may offer the best approach currently 
available. 
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Strengths and Limitations 
This study is a single center study in the southeast with a small sample in the phase-two 
DIPS study (n=85). However, when combined with the phase-one study (n=271), the sample size 
was robust at 356. Both samples did represent a diverse population, consistent with the age and 
racial ethnicities reported in the stroke literature.  
The DIPS study had a low attrition rate (3.5%). Of the three patients lost to follow-up by 
day 30, one had minor depression symptoms and two had moderate to severe depression 
symptoms during admission. It is difficult to know how these patient responses would have 
affected the data, but it is possible that higher rates of reported depression and treatment would 
have occurred at the day 30 assessment.  
In both the phase-one sample and the phase-two DIPS study sample, TIA patients may be 
under-represented. This is because suspected TIA patients completed their evaluations in the 
emergency department, thus no longer requiring admission to the hospital. Additionally, SAH 
patients experienced low enrollment in the DIPS study since they were on the neurosurgery 
service, scheduled for phase three implementation after project evaluation.   
The PHQ-9 screening tool provided results of reported depression symptoms and not a 
depression diagnosis based on DSM criteria structured interviews. The PHQ-9 is a retrospective 
evaluation of symptoms over the last two weeks. Therefore, it may be difficult for patients to 
consider the “last two weeks” right after a major life event, which could possibly inflate the rates 
of depression symptoms reported during hospitalization. However, the PHQ-9 screening tool is 
based on DSM symptomatology criteria, with good sensitivity (0.86) and specificity (0.79) 
ratings (Meader, Moe-Byrne, Llewellyn, & Mitchell (2014) and recommended as one of the 
three most appropriate for evaluating PSD (Towfighi et al., 2016). Trained research staff, 
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knowledgeable of stroke patients, assisted with completing the PHQ-9 to maintain consistency. 
Additionally, to improve inter-rater reliability for NIHSS and mRS assessment, all study 
personnel completed certification training. In addition, all neurology physicians and 
neuroscience nurses hold NIHSS certification. No validity or reliability data exists for the staff 
satisfaction questionnaires.  
Limitations of project implementation pertained to difficulties and inabilities to change 
the electronic medical record in a timely manner. However, nursing leadership acting as change 
agents negotiated and developed acceptable solutions to this barrier. Exceptional results should 
be taken with caution. A robust research team supported target groups, physicians and nurses, 
increasing communication and possibly effecting screening rates. Additionally, centers may not 
have a stroke NP to assist with follow-up post discharge.  
Suggestions for Future Research/Quality Improvement 
Further research to determine optimal time to administer the PHQ-9 during 
hospitalization will assist clinicians to appropriately detect and treat PSD and conserve staff 
resources. Improvement in methodology with strict control over assessment timing and 
assistance only by the research team will improve reliability and decrease bias.  
Further statistical analysis on the correlation between the proxy and patient is important 
to determine agreement at the question level. Continued evaluation of patients with minor 
depression symptoms and proxy burden is key to understanding the difficulties in agreement 
between patient and proxy in certain domains as mood, emotion and energy (Skolarus, et al., 
2010). Additionally, the integration of patient and proxy scores needs further exploration to 
determine the combined PHQ-9 reliability and validity.  
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Although the DIPS study sample was not powered to validate the DFSS model, the 
phase-one sample, followed for six months, may provide sufficient information. Examining the 
data to determine if there was an improvement in patients treated for depression and receiving 
rehabilitation compared to patients that did not may provide further validation of the model. 
Goals of Dissemination 
The primary goal of the dissemination plan is to share the DIPS protocol with stroke 
centers and national organizations to improve understanding of the detrimental effects of PSD 
and improve mental health care of stroke survivors. Sharing the information with national 
organizations, such as the American Heart Association/American Stroke Association 
(AHA/ASA) and certifying bodies, such as The Joint Commission (TJC), will reach a larger 
audience and may be the impetus for further standards leading to improved post-stroke mental 
health care nationally.  
Dissemination of DIPS has already begun. Neurology residents received outcome data on 
October 2, 2017 during the weekly resident lecture series. Staff from the stroke center and 
neuroscience nurses attended the Nov 6, 2017 final defense in support of the project. 
Presentation of project findings to system hospital’s stroke programs will occur on December 1, 
2017 with active discussion planned on implementation at system hospitals. The Joint 
Commission has requested posting of study findings as an educational module for stroke 
surveyors by December 31, 2017 and DIPS will be presented at the 2018 Mid-Atlantic Heart and 
Stroke Quality Summit on April 26, 2018. DIPS data will be shared on the stroke center website 
and presentations to the stroke support groups and the UNC Stroke Advisory Board in 2018 are 
in the discussion phase.  
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Conclusion 
 The Joint Commission mandates that certified comprehensive stroke centers 
screen all stroke patients for depression prior to discharge, yet there is no standard regarding 
when to screen and treat. Phase one of this study found a high prevalence of depression 
symptoms reported during hospitalization, but low treatment rates. Additionally, in the combined 
samples, PSD patients were more likely disabled and discharged to a SNF.  
The study suggests that implementation of an evidenced-based depression screening and 
treatment algorithm can improve detection of depression symptoms and treatment of PSD during 
the acute phase of hospitalization. Further research on the appropriate timing of screening during 
hospitalization exists and there may be a clinical rationale for repeated administration of the 
PHQ-9 during acute hospitalization since the second screening scores increased and new cases 
were identified at day seven and day 30.   
The most impactful change with implementing DIPS was a standardized assessment and 
treatment algorithm with increased adherence to best practice recommendations. DIPS 
standardized roles, integrated the care team, provided patient-centered care and was sustainable 
using current staff with no additional costs.  
The literature and data from this study highlight the importance of having an appropriate 
process in place during hospitalization that offers depression screening, treatment and follow-up 
after discharge. Given the association of poor functional recovery, increased mortality, increased 
healthcare costs and low side effect risk, establishing a plan for screening and treatment during 
acute hospitalization should be standard practice. Based on study findings, a recommendation to 
stroke certification bodies, such as The Joint Commission and Det Norske Veritas (DNV), 
include a performance standard that specifically addresses treatment initiation for PSD.  
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APPENDIX 2: PSD ASSESSMENT TOOLS 
Scale Name Scale 
Abbreviation 
Measure Range Threshold Sensitivity 
and 
Specificity 
Center of 
Epidemiological 
Studies-
Depression 
Scale 
CES-D 20-item 
questionnaire 
measuring 
symptoms of 
depression 
0-60 > 16 signifies 
depression 
0.86/0.90 
Hamilton 
Depression 
Rating Scale 
HDRS 17-item 
questionnaire 
measuring level 
of depression 
0-52 0-7=normal; 8-
13=mild; 14-
18=moderate; 19-
22=severe; > 
23=very severe 
depression 
0.85/0.79 
Patient Health 
Questionnaire-9 
PHQ-9 9-item 
questionnaire 
measuring the 
nine symptoms 
of depression 
based on DSM 
criteria 
0-27 0=no depression; 
1-4 minimum 
depression; 5-9 
mild depression; 
10-14 moderate 
depression; 15-19 
moderately 
severe 
depression; 20-27 
severe depression  
0.86/0.79 
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APPENDIX 3: FUNCTIONAL STATUS ASSESSMENT TOOLS 
Scale Name Scale 
Abbreviation 
Measure Range Threshold Sensitivity 
and 
Specificity 
Barthel Index BI Measure of 
functional 
independence in 
activities of daily 
living 
0-100 0-50=severe 
impairment;  
51-75=moderate;  
76-100=mild 
impairment 
0.94/0.80 
Functional 
Independence 
Measure 
FIM Evaluates 
physical and 
cognitive 
disability based 
on the burden of 
caring for a 
patient 
18-
126 
18 = total care; 
126 = independent 
 
0.76/0.64 
Fugl-Meyer 
Assessment of 
Motor 
Recovery After 
Stroke 
FMA Lengthy and 
requires a trained 
physical 
therapist, 
evaluates motor, 
joint, balance and 
sensation after 
stroke  
 
0-100 < 50 = severe 
motor impairment; 
50-84 = marked 
motor impairment; 
85-95 = moderate 
impairment;  
96-99 = slight 
impairment;  
100 = normal 
0.77/0.89 
Modified 
Rankin Scale 
mRS Evaluates 
independence and 
global disability 
0-6 0 = no disability; 
1=mild symptom 
self-care; 2= some 
assistance; 3= 
needs assistance 
walking; 4= not 
walking; 5=total 
nursing care;  
6= dead 
0.85/0.87 
National 
Institutes of 
Health Stroke 
Scale 
NIHSS Graded physical 
exam of stroke 
severity 
0-42 0 = normal;  
1-4=minor;  
5-15=moderate;  
16-20=moderately 
severe;  
> 20=severe stroke 
0.72/0.89 
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APPENDIX 4: DEPRESSION AND FUNCTIONAL STATUS IN STROKE SURVIVORS 
MODEL 
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APPENDIX 5: DIPS CONCEPT MAP 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
 
PHQ-9 Assessment 
APPENDIX 6: DIPS TREATMENT ALGORITHM 
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APPENDIX 7: PHASE-ONE STUDY IRB APPROVAL LETTER 
 
OFFICE OF HUMAN 
RESEARCH ETHICS 
105 Mason Farm Road 
Medical Building #52 
CB #7097 
University of North Carolina 
at Chapel Hill Chapel Hill, 
North Carolina 27599-7097 
(919) 966-3113 
Web site: ohre.unc.edu 
Federal wide Assurance 
(FWA) #4801 
 
To: Susan Wilson  
Neurology 
 
From: IRB 
Approval Date: 7/11/2014 
Expiration Date of Approval: 7/10/2015 
RE: Notice of IRB Approval by Expedited Review (under 45 CFR 46.110) 
Submission Type: Initial 
Expedited Category: 7.Surveys/interviews/focus groups 
Study #: 14-1380 
 
Study Title: Depression Screening in Acute Stroke Patients 
 
This submission has been approved by the IRB for the period indicated. It has been 
determined that the risk involved in this research is no more than minimal. 
 
Study Description: 
Purpose: 1. To assess the prevalence and incidence of depression in the UNC stroke 
population pre- and post-stroke.  2. Describe depression after stroke. 
 
Participants: Stroke patients admitted to UNC HealthCare 
 
Procedures (methods):Patients admitted to UNC Healthcare under the care of the 
Department of Neurology and /or Department of Neurosurgery will be screened for 
depression using the PHQ-9 assessment tool. Upon discharge, the patient will receive a 
phone call within followup time periods and the PHQ-9 will be administered. The 
PHQ-9 will also be administered to the family/caregiver as a patient-proxy.  A six-
month phone follow-up will complete the study. 
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Investigator’s Responsibilities: 
Federal regulations require that all research be reviewed at least annually. It is the 
Principal Investigator’s responsibility to submit for renewal and obtain approval 
before the expiration date. You may not continue any research activity beyond the 
expiration date without IRB approval. 
Failure to receive approval for continuation before the expiration date will result in 
automatic termination of the approval for this study on the expiration date. 
 
Your approved consent forms and other documents are 
available online at 
http://apps.research.unc.edu/irb/irb_event.cfm?actn=info&ir
bid=14-1380. 
 
You are required to obtain IRB approval for any changes to any aspect of this study 
before they can be implemented. Any unanticipated problem involving risks to subjects 
or others (including adverse events reportable under UNC-Chapel Hill policy) should 
be reported to the IRB using the web portal   at http://irbis.unc.edu. 
 
Please be aware that additional approvals may still be required from other relevant 
authorities or "gatekeepers" (e.g., school principals, facility directors, custodians of 
records). 
 
This study was reviewed in accordance with federal regulations governing human 
subjects research, including those found at 45 CFR 46 (Common Rule), 45 CFR 164 
(HIPAA), 21 CFR 50 & 56 (FDA), and 40 CFR 26 (EPA), where applicable. 
 
CC: 
Natalie Aucutt-Walter, Neurology  
Anne Beckwith, Neurology  
Octavio De Marchena, Neurology  
David Huang, Neurology 
Angela Lipscomb-Hudson, Physical Medicine and Rehabilitation  
Leonardo Morantes Gomez, Neurology 
Kevin Robertson, Neurology 
Karla Thompson, Physical Medicine and Rehabilitation  
Michael Wang, Neurology 
Vincent Woolfolk, Neurology
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APPENDIX 8: PHASE-ONE IRB APPROVED CONSENT FORM 
 
University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study  
Adult Participants  
 
Consent Form Version Date: __7.7.14____________ 
IRB Study #: 14-1380 
Title of Study: Depression Screening in Stroke Patients 
Principal Investigator: Susan Wilson, RN, MSN, C-ANP 
Principal Investigator Department: Neurology 
Principal Investigator Phone number: (919) 843-2387 
Principal Investigator Email Address: wilsons@neurology.unc.edu 
Co-Investigators: Natalie Aucutt-Walter, MD; David Huang, MD, PhD; Michael Wang, 
MD; Octavio de Marchena, MD; Leo Morantes Gomez, MD; Anne Beckwith BS; Vincent 
Woolfolk 
Funding Source and/or Sponsor: UNC Department of Neurology 
_________________________________________________________________ 
What are some general things you should know about research studies?  
You are being asked to take part in a research study. To join the study is voluntary.  
You may refuse to join, or you may withdraw your consent to be in the study, for any reason, 
without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future. You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies. 
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
The purpose of this research study is to determine the rate of depression before and after the 
diagnosis of stroke as well as the time course of development.  
 
Post stroke depression is common; however, it is under recognized and under diagnosed. Studies 
have estimated post-stroke depression to occur in 33% of survivors.  Depression is associated 
with poorer outcomes, recovery and quality of life. For this reason, early screening and treatment 
is important.  Starting treatment early, within the first month after stroke diagnosis, is more 
effective and associated with improved functional outcomes.  
 
Are there any reasons you should not be in this study?  
You should not be in this study if: 
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• You are less than 18 years old 
• You do not have a suspected or confirmed diagnosis of stroke or trans ischemic attack 
(TIA) 
• You are not able to participate in the study for 6 months 
How many people will take part in this study?  
Approximately 650 people will take part in this study at UNC Hospitals.  
 
How long will your part in this study last?  
This study will follow you for 6 months.  
 
What will happen if you take part in the study?  
The following information and procedures will be obtained by the study team. 
 
a. Admission 
• Demographics (name, age and phone numbers) (standard of care) 
• Name of primary physician (standard of care) 
• Medical history (standard of care) 
• Current medications (standard of care) 
• Functional assessment of how well you were doing prior to your stroke, called 
pre-modified rankin (pre-mRS) (standard of care) 
• Neurological physical exam called National Institutes of Health Stroke Scale 
(NIHSS) (standard of care)  
• Patient Health Questionnaire 2 (PHQ-2) – 2 questions performed by admitting 
nurse (standard of care per UNC Stroke Center) 
• Patient Health Questionnaire 9 (PHQ-9) – completed by patient with 
assistance by study team 
• PHQ-9 - completed by family/caregiver  
 
b. 7 (+/- 3) day Phone Call post Discharge 
• Complete PHQ-9 by patient 
• Complete PHQ-9 by family/caregiver  
• mRS (standard of care) 
• Study team will question if participating in rehabilitation therapy (standard of 
care) 
• Study team will question if participating in psychological counseling (standard 
of care) 
 
c. 30 (+/- 5) day Phone Call or Clinic Follow-up 
• Complete PHQ-9 by patient 
• Complete PHQ-9 by family/caregiver  
• mRS 
• Study team will question if participating in rehabilitation therapy 
• Study team will question if participating in psychological counseling 
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d. 60 (+/- 7) day Phone Call 
• Complete PHQ-9 by patient 
• Complete PHQ-9 by family/caregiver  
• mRS 
• Study team will question if participating in rehabilitation therapy 
• Study team will question if participating in psychological counseling 
 
e. 90 (+/- 7) day Phone Call 
• Complete PHQ-9 by patient 
• Complete PHQ-9 by family/caregiver  
• mRS  
• Study team will question if participating in rehabilitation therapy 
• Study team will question if participating in psychological counseling 
 
f. 6 (+/- 10 days) month Phone Call 
• Complete PHQ-9 by patient 
• Complete PHQ-9 by family/caregiver  
• mRS 
• Study team will question if participating in rehabilitation therapy 
• Study team will question if participating in psychological counseling 
• Study team will question about any hospitalizations or new diagnosis  
What are the possible benefits from being in this study?  
It is not possible to predict whether you will benefit directly from participation in this 
study. However, your participation may help others in the future as a result of knowledge gained 
from the research. 
 
What are the possible risks or discomforts involved from being in this study?  
As a result of your participation in this study, you are at risk for side-effects listed in this 
section. You should discuss these with the investigator.  It is important that you consider all of 
the options before you decide to participate in this research study. 
  
Loss of Confidentiality:  
There is the potential for loss of confidentiality by participating in this study. Every effort will be 
made to protect the confidentiality of your identifiable information. However, if your 
participation becomes known, it could create a problem or hardship for you depending upon the 
type of information disclosed.  
  
We will take every measure to protect your privacy and confidentiality. Any information will be 
coded by a study-specific identification number to protect your confidentiality. Any information 
stored by the study team will be stored in a locked filing cabinet in a building that is locked to 
the public. Any electronic data will be stored on a protected server. Study documentation will be 
kept and securely archived. Your identity will be kept confidential when the results of this study 
are published. 
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When telephoning, the study staff will ask if it is a convenient time and will call back if it is 
not. No messages will be left pertaining to this study.  
  
Psychological Stress:  
Some of the questions we will ask you as part of this study may make you feel uncomfortable. 
You may refuse to answer any of the questions and you may take a break at any time during the 
interview. You may stop your participation in the study at any time. 
 
There may be uncommon or previously unknown risks. You should report any problems to the 
researcher. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.  
 
How will your privacy be protected?  
Participants will not be identified in any report or publication about this study. Although every 
effort will be made to keep research records private, there may be times when federal or state law 
requires the disclosure of such records, including personal information.  This is very unlikely, 
but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to protect 
the privacy of personal information.  In some cases, your information in this research study could 
be reviewed by representatives of the University for the purpose of quality control or safety.  
Confidentiality of your records will be strictly maintained. Your information will be kept in 
locked offices, and on computers that are password protected. A copy of this consent form will 
go into your medical record. This will allow the doctors caring for you to know what study 
questionnaires you may be receiving as a part of the study. 
 
What will happen if you are injured by this research?  
 All research involves a chance that something bad might happen to you.  This may include the 
risk of personal injury.  If such problems occur, the researcher will help you get medical care, but 
The University of North Carolina at Chapel Hill has not set aside funds to pay you for any such 
reactions or injuries, or for the related medical care. 
 
Any costs for medical expenses not paid by UNC will be billed to you or your insurance 
company. You do not give up any of your legal rights by signing this form. 
 
What if you want to stop before your part in the study is complete?  
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have failed to follow 
instructions, or because the entire study has been stopped.  
Will you receive anything for being in this study?  
You will not receive anything for taking part in this study. 
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Will it cost you anything to be in this study?  
It will not cost you anything for taking part in this study. 
 
Who is sponsoring this study?  
There is no funding for this study.  The UNC Department of Neurology Stroke Center is 
sponsoring this study to gain knowledge in order to improve care to all stroke patients treated at 
UNC HealthCare.  
 
What if you have questions about this study?  
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study, complaints, or concerns, you should contact the researchers 
listed on the first page of this form. 
 
What if you have questions about your rights as a research participant?  
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 
at 919-966-3113 or by email to IRB_subjects@unc.edu. 
 
Participant’s Agreement: 
I have read the information provided above.  I have asked all the questions I have at this time.  I 
voluntarily agree to participate in this research study. 
_____________________________________________________ 
Signature of Research Participant 
____________________ 
Date 
 
 
_____________________________________________________ 
Printed Name of Research Participant 
  
 
 
______________________________________________________ 
Signature of Legally Authorized Representative 
____________________ 
Date 
_______________________________________ 
Printed Name of Legally Authorized Representative   
_______________________________________________________ 
(Relationship to subject) 
______________________________________________________ 
Signature of Research Team Member Obtaining Consent 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
  
______________________________________________________ 
Signature of Impartial Witness 
___________________ 
  Date 
 
______________________________________________________ 
Printed Name of Impartial Witness 
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APPENDIX 9: PHASE-ONE IRB APPROVED HIPAA FORM 
University of North Carolina at Chapel Hill 
HIPAA Authorization for Use and Disclosure of Health Information for Research Purposes 
 
IRB Study #: 14-1380 
Title of Study: Depression Screening in Stroke Patients  
Principal Investigator: Susan Wilson RN, MSN, C-ANP     
Mailing Address for UNC-Chapel Hill Department: CB:7025 Neurology, Physicians Office Bldg , 170 
Manning Drive ,Chapel Hill, NC 27599-7025 , USA      
 
This is a permission called a “HIPAA authorization.”  It is required by the “Health Insurance Portability 
and Accountability Act of 1996” (known as “HIPAA”) in order for us to get information from your 
medical records or health insurance records to use in this research study.  
 
1. If you sign this HIPAA authorization form, you are giving your permission for the following 
people or groups to give the researchers certain information about you (described below): 
 
Any health care providers or health care professionals that have provided health services or 
treatment, such as physicians, clinics, hospitals, home health agencies, diagnostic centers, 
laboratories, treatment or surgical centers associated with UNC Health Care System. 
 
2. If you sign this form, this is the health information about you that the people or groups listed 
in #1 may give to the researchers to use in this research study: 
 
Information about your stroke or TIA.  This would include information about medical treatment 
and rehabilitation as well as any information in your medical records that relates to your 
participation in this research.  These records might include information about mental health, drug 
or alcohol use, HIV/AIDS or other communicable diseases.  
 
3. The HIPAA protections that apply to your medical records will not apply to your information 
when it is in the research study records.  Your information in the research study records may also 
be shared with, used by or seen by collaborating researchers and certain employees of the 
university if needed to oversee the research study.  HIPAA rules do not usually apply to those 
people or groups. If any of these people or groups reviews your research record, they may also 
need to review portions of your original medical record relevant to the situation.  The informed 
consent document describes the procedures in this research study that will be used to protect 
your personal information. You can also ask the researchers any questions about what they will 
do with your personal information and how they will protect your personal information in this 
research study. 
 
HIPAA regulations require that we let people know that sharing the PHI with others who are not 
covered by HIPAA – such as pharmaceutical company sponsors – will take that PHI outside of 
HIPAA’s coverage.  For example, HIPAA generally requires authorization or waiver of 
authorization as well as certain accounting records for disclosures of individually identifiable 
information from the medical record, but these HIPAA requirements do not apply to the same 
individually identifiable health information in the research database. The natural concern for the 
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research subject is whether this means that there are no confidentiality protections once the PHI 
has been shared outside of HIPAA coverage.  The researcher should explain what confidentiality 
protections have been set up for the individually identifiable information in this study.  In 
addition to the research study procedures to protect confidentiality, our standard clinical trial 
language requires the sponsor to protect the confidentiality of any individually identifiable data. 
 
4. If this research study creates medical information about you that will go into your medical 
record, you may not be able to see the research study information in your medical record until 
the entire research study is over. 
 
5. If you want to participate in this research study, you must sign this HIPAA authorization form 
to allow the people or groups listed in #1 on this form to give access to the information about 
you that is listed in #2.  If you do not want to sign this HIPAA authorization form, you cannot 
participate in this research study. However, not signing the authorization form will not change 
your right to treatment, payment, enrollment or eligibility for medical services outside of this 
research study. 
 
6.  This HIPAA authorization will not stop unless you stop it in writing. 
 
7. You have the right to stop this HIPAA authorization at any time.   You must do that in 
writing.  You may give your written stop of this HIPAA authorization directly to Principal 
Investigator or researcher or you may mail it to the department mailing address listed at the top 
of this form, or you may give it to one of the researchers in this study and tell the researcher to 
send it to any person or group the researcher has given a copy of this HIPAA 
authorization.  Stopping this HIPAA authorization will not stop information sharing that has 
already happened.  
 
8. You will be given a copy of this signed HIPAA authorization.  
 
______________________________________________________ 
Signature of Research Subject 
 
  ____________________ 
   Date 
 
______________________________________________________ 
Print Name of Research Subject 
  
 
 
For Personal Representative of the Research Participant (if applicable) 
 
Print Name of Personal Representative: ___________________________ 
Please explain your authority to act on behalf of this Research Subject: 
____________________________________________________________ 
 
I am giving this permission by signing this HIPAA Authorization on behalf of the Research Participant.  
 
______________________________________________________ 
Signature of Personal Representative 
 
   ____________________ 
   Date 
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APPENDIX 10: PHASE-TWO DIPS IRB APPROVAL LETTER 
OFFICE OF HUMAN 
RESEARCH ETHICS 
720 Martin Luther King, Jr. 
Blvd. Bldg. 385, 2nd Floor 
CB #7097 
Chapel Hill, NC 27599-7097 
(919) 966-3113 
Web site: ohre.unc.edu 
Federalwide Assurance 
(FWA) #4801 
 
To: Susan Wilson 
Neurology 
 
From: Non-Biomedical IRB 
 
Approval Date: 3/20/2017 
Expiration Date of Approval: 5/25/2017 
RE: Notice of IRB Approval by Expedited Review (under 45 CFR 46.110) 
Submission Type: Modification 
Expedited Category: 7.Surveys/interviews/focus groups, Minor Change to Previously 
Approved Research 
Study #: 14-1380 
 
Study Title: Depression Improvement Program in Stroke (DIPS) 
 
This submission has been approved by the IRB for the period indicated. It has been 
determined that the risk involved in this modification is no more than minimal. 
Unless otherwise noted, regulatory and other findings made previously for this study 
continue to be applicable. 
 
Submission Description: 
Based on data gathered during this study, depressive symptoms occur 30-54% in 
stroke patients admitted to UNC HealthCare, yet less than 39% are treated. Post-stroke 
depression (PSD) is associated with increased mortality, negative impact on recovery, 
higher hospital costs and stroke recurrence.  This study extension will evaluate 
physician utilization of a treatment algorithm based on PHQ-9 scoring. Nursing will 
assess the patient at admission as standard of care using the PHQ-9.  The study will 
continue consenting the patient and caregiver for an additional PHQ-9 assessment 
performed during admission to evaluate if timing is a factor in development of PSD 
symptoms (admission vs 3-4 days later). Follow-up assessments will continue through 
day 30.  This study is discontinuing the day 60, 90 and 6-month follow-up.  Every 
effort will be made to include the patients PCP as was performed in the original study. 
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New personnel added include Mary Lynn Piven, PhD, RN; Rebecca Kitzmiller, PhD, 
RN; Michael Forbes, MD 
 
Investigator’s Responsibilities: 
If applicable, your approved consent forms and other documents are available online 
at 
http://apps.research.unc.edu/irb/index.cfm?event=home.dashboard.irbStudyManage
ment&irb_id=14-1380. 
 
The current data security level determination is Level III. Any changes in the data 
security level need to be discussed with the relevant IT official. If data security level 
II and III, consult with your IT official to develop a data security plan. Data security 
is ultimately the responsibility of the Principal Investigator. 
 
This study was reviewed in accordance with federal regulations governing human 
subjects research, including those found at 45 CFR 46 (Common Rule), 45 CFR 164 
(HIPAA), 21 CFR 50 & 56 (FDA), and 40 CFR 26 (EPA), where applicable. 
 
CC: 
Anne Beckwith, Neurology 
Ariane Cook, Neurology 
Michael Cools, Neurosurgery Clinic  
Octavio De Marchena, Neurology  
Michael Forbes, Neurology 
David Huang, Neurology 
Rebecca Kitzmiller, School of Nursing  
Laura Pinto-Coelho, Neurology 
Mary Piven, School of Nursing  
Kevin Robertson, Neurology 
Deanna Sasaki-Adams, Neurosurgery Clinic  
Michael Wang, Neurology
 
 
APPENDIX 11: PHASE-TWO DIPS IRB APPROVED CONSENT FORM 
University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study  
Adult Participants  
 
Consent Form Version Date: __4.9.17____________ 
IRB Study #: 14-1380 
Title of Study: Depression Improvement Program in Stroke (DIPS) 
Principal Investigator: Susan Wilson, RN, MSN, C-ANP 
Principal Investigator Department: Neurology 
Principal Investigator Phone number: (919) 843-2387 
Principal Investigator Email Address: wilsons@neurology.unc.edu 
Co-Investigators: David Huang, MD, PhD; Michael Wang, MD; Octavio de Marchena, 
MD; Michael Forbes, MD; Anne Beckwith BS; Laura Pinto-Coelho, BA; Laura Weng; 
Meghan McPeak; Mary Lynn Piven PhD, RN; Rebecca Kitzmiller, PhD, RN 
Funding Source and/or Sponsor: UNC Department of Neurology 
_________________________________________________________________ 
What are some general things you should know about research studies?  
You are being asked to take part in a research study. To join the study is voluntary. 
You may refuse to join, or you may withdraw your consent to be in the study, for any reason, 
without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies. 
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
The purpose of this research study is to evaluate the implementation of an assessment and 
treatment plan with the goal of standardizing psychological care for stroke patients.  
 
Post stroke depression is common; however, it is under recognized and under diagnosed. Studies 
have estimated post-stroke depression to occur in 33% of survivors.  Depression is associated 
with poorer outcomes, recovery and quality of life. For this reason, early screening and treatment 
is important.  Starting treatment early, within the first month after stroke diagnosis, is more 
effective and associated with improved functional outcomes.  
 
Are there any reasons you should not be in this study?  
You should not be in this study if: 
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• You are less than 18 years old 
• You do not have a suspected or confirmed diagnosis of stroke or trans ischemic attack 
(TIA) 
• You are not able to participate in the study for 30 days 
How many people will take part in this study?  
Approximately 375 people will take part in this study at UNC Hospitals.  
 
How long will your part in this study last?  
This study will follow you for 30 days.  
 
What will happen if you take part in the study?  
The following information and procedures will be obtained by the study team. 
 
g. Admission 
• Demographics (name, age and phone numbers) (standard of care) 
• Name of primary physician (standard of care) 
• Medical history (standard of care) 
• Current medications (standard of care) 
• Functional assessment of how well you were doing prior to your stroke, called 
pre-modified rankin (pre-mRS) (standard of care) 
• Neurological physical exam called National Institutes of Health Stroke Scale 
(NIHSS) (standard of care)  
• Patient Health Questionnaire 9 (PHQ-9) – completed by patient with 
assistance of admitting nurse (standard of care) 
• Patient Health Questionnaire 9 (PHQ-9) – completed by patient with 
assistance by study team 
• PHQ-9 - completed by family/caregiver  
 
h. 7 (+/- 3) day Phone Call post Discharge 
• Complete PHQ-9 by patient 
• Complete PHQ-9 by family/caregiver  
• mRS (standard of care) 
• Study team will ask if participating in rehabilitation therapy (standard of care) 
• Study team will ask if participating in psychological counseling (standard of 
care) 
• Medication use will be reviewed (standard of care) 
 
i. 30 (+/- 5) day Phone Call or Clinic Follow-up 
• Complete PHQ-9 by patient 
• Complete PHQ-9 by family/caregiver  
• mRS 
• Study team will ask if participating in rehabilitation therapy 
• Study team will ask if participating in psychological counseling 
• Review medication use 
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• Study team will ask about hospitalizations or new diagnosis since discharge 
 
What are the possible benefits from being in this study?  
It is not possible to predict whether you will benefit directly from participation in this 
study.  However, early identification of depression and treatment has been shown to be beneficial 
to stroke recovery.  In addition, your participation may help others in the future as a result of 
knowledge gained from the research. 
 
What are the possible risks or discomforts involved from being in this study?  
As a result of your participation in this study, you are at risk for side-effects listed in this 
section.  You should discuss these with the investigator.  It is important that you consider all of 
the options before you decide to participate in this research study. 
  
Loss of Confidentiality:  
There is the potential for loss of confidentiality by participating in this study. Every effort will be 
made to protect the confidentiality of your identifiable information.  However, if your 
participation becomes known, it could create a problem or hardship for you depending upon the 
type of information disclosed.  
  
We will take every measure to protect your privacy and confidentiality. Any information will be 
coded by a study-specific identification number to protect your confidentiality.  Any information 
stored by the study team will be stored in a locked filing cabinet in a building that is locked to 
the public.  Any electronic data will be stored on a protected server.  Study documentation will 
be kept and securely archived.  Your identity will be kept confidential when the results of this 
study are published. 
  
When telephoning, the study staff will ask if it is a convenient time and will call back if it is 
not. No messages will be left pertaining to this study.  
  
Psychological Stress:  
Some of the questions we will ask you as part of this study may make you feel uncomfortable. 
You may refuse to answer any of the questions and you may take a break at any time during the 
interview.  You may stop your participation in the study at any time. 
 
There may be uncommon or previously unknown risks. You should report any problems to the 
researcher. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.  
 
How will your privacy be protected?  
Participants will not be identified in any report or publication about this study. Although every 
effort will be made to keep research records private, there may be times when federal or state law 
requires the disclosure of such records, including personal information.  This is very unlikely, 
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but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to protect 
the privacy of personal information.  In some cases, your information in this research study could 
be reviewed by representatives of the University for the purpose of quality control or safety.  
Confidentiality of your records will be strictly maintained. Your information will be kept in 
locked offices, and on computers that are password protected. A copy of this consent form will 
go into your medical record. This will allow the doctors caring for you to know what study 
questionnaires you may be receiving as a part of the study. 
 
What will happen if you are injured by this research?  
All research involves a chance that something bad might happen to you.  This may include the 
risk of personal injury.  If such problems occur, the researcher will help you get medical care, but 
The University of North Carolina at Chapel Hill has not set aside funds to pay you for any such 
reactions or injuries, or for the related medical care. 
 
Any costs for medical expenses not paid by UNC will be billed to you or your insurance 
company. You do not give up any of your legal rights by signing this form. 
 
What if you want to stop before your part in the study is complete?  
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have failed to follow 
instructions, or because the entire study has been stopped.  
Will you receive anything for being in this study?  
You will not receive anything for taking part in this study. 
 
Will it cost you anything to be in this study?  
It will not cost you anything for taking part in this study. 
 
Who is sponsoring this study?  
There is no funding for this study.  The UNC Department of Neurology Stroke Center is 
sponsoring this study to gain knowledge in order to improve care to all stroke patients treated at 
UNC HealthCare.  
 
What if you have questions about this study?  
You have the right to ask, and have answered, any questions you may have about this research. If 
you have questions about the study, complaints, or concerns, you should contact the researchers 
listed on the first page of this form. 
 
What if you have questions about your rights as a research participant?  
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 
at 919-966-3113 or by email to IRB_subjects@unc.edu. 
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Participant’s Agreement: 
I have read the information provided above.  I have asked all the questions I have at this time.  I 
voluntarily agree to participate in this research study. 
  
______________________________________________________ 
Signature of Research Participant 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Participant 
  
  
______________________________________________________ 
Signature of Legally Authorized Representative 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Legally Authorized Representative 
  
_______________________________________________________ 
(Relationship to subject) 
  
______________________________________________________ 
Signature of Research Team Member Obtaining Consent 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
  
  
  
______________________________________________________ 
Signature of Impartial Witness 
 
 
____________________ 
  Date 
 
______________________________________________________ 
Printed Name of Impartial Witness 
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APPENDIX 12: PHASE-TWO DIPS IRB APPROVED HIPAA FORM 
University of North Carolina at Chapel Hill 
HIPAA Authorization for Use and Disclosure of Health Information for Research Purposes 
 
IRB Study #: 14-1380 
Title of Study: Depression Improvement Program in Stroke  
Principal Investigator: Susan Wilson RN, MSN, C-ANP     
Mailing Address for UNC-Chapel Hill Department: CB:7025 Neurology, Physicians Office Bldg , 170 
Manning Drive, Chapel Hill, NC 27599-7025, USA      
 
This is a permission called a “HIPAA authorization.”  It is required by the “Health Insurance Portability 
and Accountability Act of 1996” (known as “HIPAA”) in order for us to get information from your 
medical records or health insurance records to use in this research study.  
 
1. If you sign this HIPAA authorization form, you are giving your permission for the following 
people or groups to give the researchers certain information about you (described below): 
 
Any health care providers or health care professionals that have provided health services or 
treatment, such as physicians, clinics, hospitals, home health agencies, diagnostic centers, 
laboratories, treatment or surgical centers associated with UNC Health Care System. 
 
2. If you sign this form, this is the health information about you that the people or groups listed 
in #1 may give to the researchers to use in this research study: 
 
Information about your stroke or TIA.  This would include information about medical treatment 
and rehabilitation as well as any information in your medical records that relates to your 
participation in this research.  These records might include information about mental health, drug 
or alcohol use, HIV/AIDS or other communicable diseases.  
 
3. The HIPAA protections that apply to your medical records will not apply to your information 
when it is in the research study records.  Your information in the research study records may also 
be shared with, used by or seen by collaborating researchers and certain employees of the 
university if needed to oversee the research study.  HIPAA rules do not usually apply to those 
people or groups. If any of these people or groups reviews your research record, they may also 
need to review portions of your original medical record relevant to the situation.  The informed 
consent document describes the procedures in this research study that will be used to protect 
your personal information. You can also ask the researchers any questions about what they will 
do with your personal information and how they will protect your personal information in this 
research study. 
 
HIPAA regulations require that we let people know that sharing the PHI with others who are not 
covered by HIPAA – such as pharmaceutical company sponsors – will take that PHI outside of 
HIPAA’s coverage.  For example, HIPAA generally requires authorization or waiver of 
authorization as well as certain accounting records for disclosures of individually identifiable 
information from the medical record, but these HIPAA requirements do not apply to the same 
individually identifiable health information in the research database. The natural concern for the 
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research subject is whether this means that there are no confidentiality protections once the PHI 
has been shared outside of HIPAA coverage.  The researcher should explain what confidentiality 
protections have been set up for the individually identifiable information in this study.  In 
addition to the research study procedures to protect confidentiality, our standard clinical trial 
language requires the sponsor to protect the confidentiality of any individually identifiable data. 
 
4. If this research study creates medical information about you that will go into your medical 
record, you may not be able to see the research study information in your medical record until 
the entire research study is over. 
 
5. If you want to participate in this research study, you must sign this HIPAA authorization form 
to allow the people or groups listed in #1 on this form to give access to the information about 
you that is listed in #2.  If you do not want to sign this HIPAA authorization form, you cannot 
participate in this research study. However, not signing the authorization form will not change 
your right to treatment, payment, enrollment or eligibility for medical services outside of this 
research study. 
 
6.  This HIPAA authorization will not stop unless you stop it in writing. 
 
7. You have the right to stop this HIPAA authorization at any time.   You must do that in 
writing.  You may give your written stop of this HIPAA authorization directly to Principal 
Investigator or researcher or you may mail it to the department mailing address listed at the top 
of this form, or you may give it to one of the researchers in this study and tell the researcher to 
send it to any person or group the researcher has given a copy of this HIPAA 
authorization.  Stopping this HIPAA authorization will not stop information sharing that has 
already happened.  
 
8. You will be given a copy of this signed HIPAA authorization. 
 
______________________________________________________ 
Signature of Research Subject 
 
 ___________________ 
   Date 
 
______________________________________________________ 
Print Name of Research Subject 
  
 
For Personal Representative of the Research Participant (if applicable) 
 
Print Name of Personal Representative: ___________________________ 
 
Please explain your authority to act on behalf of this Research Subject: 
___________________________________________________________ 
I am giving this permission by signing this HIPAA Authorization on behalf of the Research Participant. 
 
______________________________________________________ 
Signature of Personal Representative 
 ____________________ 
   Date 
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APPENDIX 13: NEUROLOGY SITE LETTER OF SUPPORT 
 
 
 
January 27, 2017 
Dr. Mary Lynn Piven, PhD, RN, CS 
DNP Project Committee 
UNC School of Nursing  
 
RE: Susan E. Wilson RN, MSN, C-ANP DNP Project 
Dear Selection Committee, 
I am writing this letter in strong support of Susan (Suzi) Wilson and her DNP project proposal entitled 
“DIPS: The Depression Improvement Program in Stroke,” which is aimed at improving the identification 
and early treatment of post-stroke depression (PSD) at UNC.  PSD is underdiagnosed throughout the US, 
and efforts to address this problem are just beginning at the national level.  Here at UNC, Suzi has led 
research into the natural history of PSD and is the PI of an IRB-approved clinical study that has enrolled 
over 200 patients to date.  From her efforts, the UNC Stroke Center has identified gaps in our 
identification and treatment of PSD, which Suzi proposes to address as a means of further improving 
functional outcomes in our stroke and TIA patients. 
As her immediate supervisor in my roles as Division Chief and Director of Stroke Center, I am committed 
to supporting Suzi and her identified team for this project.  She will have protected time to conduct the 
project.  I am also committed to participating in the expected activities of the project and providing 
mentorship and oversight.   
I am confident that Suzi has the skill set and drive to complete her project and that her efforts will make 
a major contribution to improving the quality of stroke care that we provide.  I am fully supportive of her 
efforts and expect that her participation will lead to myriad downstream improvements in and 
expansion of our Stroke Center improvement efforts. 
Sincerely,  
 
David Y. Huang, MD, PhD, FAHA, FANA, FAAN 
Professor and Chief, Division of Stroke and Vascular Neurology 
Director, UNC Health Care Comprehensive Stroke Center 
Department of Neurology 
The University of North Carolina at Chapel Hill 
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APPENDIX 14: SCHEDULE OF STUDY ACTIVITIES 
 
 
Study Activities Admission Day 7 Day 30 
Demographics* X   
Name of primary care provider X   
Medical History X   
Current Medications X X X 
Functional Assessment – pre-mRS X X X 
Neurological physical exam - NIHSS X   
PHQ-9 – completed by patient with assistance of nurse X   
PHQ-9 – completed by patient with assistance of 
research team 
X X X 
PHQ-9 – completed by family/caregiver X X X 
Participation in rehabilitation therapy X X X 
Participation in psychological counseling  X X 
Hospitalizations or new diagnosis   X 
*Name, age, education level, work history and phone numbers (standard of care) 
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APPENDIX 15: MODIFIED RANKIN SCALE 
 
 
Score Description 
0 No symptoms at all 
1 No significant disability despite symptoms; able to carry out all 
usual duties and activities 
2 Slight disability; unable to carry out all previous activities but able 
to look after own affairs without assistance 
3 Moderate disability requiring some help, but able to walk without 
assistance 
4 Moderate to severe disability; unable to walk without assistance and 
unable to attend to own bodily needs without assistance 
5 Severe disability; bedridden, incontinent, and requiring constant 
nursing care and attention 
6 Dead 
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APPENDIX 16: NATIONAL INSTITUTES OF HEALTH STROKE SCALE 
Category Score Description 
1a: Level of Consciousness 0 = Alert, keenly responsive 
1 = Not alert, but arousable by minor stimulation 
2 = Not alert, requires repeated stimulation to attend  
3 = Responds only with reflex motor or autonomic effects 
1b: Level of Conscious 
Questions 
0 = Answers both questions correctly 
1 = Answers one question correctly 
2 = Answers neither question correctly 
1c: Level of Conscious 
Commands 
0= Performs both task correctly 
1 = Performs one task correctly 
2 = Performs neither task correctly 
2. Best Gaze 0 = Normal 
1 = Partial gaze palsy 
2 = Forced deviation, or total gaze paresis 
3. Visual 0 = No visual loss 
1 = Partial hemianopia 
2 = Complete hemianopia 
3 = bilateral hemianopia (blind including cortical blindness) 
4. Facial Palsy 0 = Normal 
1 = Minor paralysis (flattened nasolabial fold) 
2 = Partial paralysis 
3 = Complete paralysis 
5a. Motor Arm - Left 
5b. Motor Arm - Right 
0 = No drift, holds 90° for 10 seconds 
2 = Some effort against gravity, drifts down to bed 
3 = No effort against gravity, limb falls 
4 = No movement 
9 = Amputation 
6a. Motor Leg – Left 
6b. Motor Leg - Right 
0 = No drift, holds 90° for 10 seconds 
2 = Some effort against gravity, drifts down to bed 
3 = No effort against gravity, limb falls 
4 = No movement 
9 = Amputation 
7. Limb Ataxia 0 = Absent 
1 = Present in one limb 
2 = Present in two limbs 
8. Sensory 0 = Normal 
1 = Mild to moderate sensory loss 
2 = Severe to total sensory loss 
9. Best Language 0 = No aphasia 
1 = Mild to moderate aphasia 
2 = Severe aphasia 
3 = Mute 
10. Dysarthria 0 = Normal 
1 = Mild to moderate dysarthria 
2 = Severe, patients speech is unintelligible 
9 = Intubated 
11. Extinction and Inattention 0 = Normal 
1 = Visual, tactile, auditory, or spatial inattention 
2 = Profound hemi-inattention to more than one modality 
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APPENDIX 17: PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9) 
 
Question Scoring 
 Not at 
all 
Several 
Days 
More than 
Half the Days 
Nearly 
Every Day 
1. Little interest or pleasure in doing things 0 1 2 3 
2. Feeling down, depressed, or hopeless 0 1 2 3 
3. Trouble falling or staying asleep, or 
sleeping too much 
0 1 2 3 
4. Feeling tired or having little energy 0 1 2 3 
5. Poor appetite or overeating 0 1 2 3 
6. Feeling bad about yourself or that you are a 
failure or have let yourself or your family 
down 
0 1 2 3 
7. Trouble concentrating on things, such as 
reading the newspaper or watching 
television 
0 1 2 3 
8. Moving or speaking so slowly that other 
people could have noticed. Or the opposite, 
being so fidgety or restless that you have 
been moving around a lot more than usual 
0 1 2 3 
9. Thoughts that you would be better off 
dead, or of hurting yourself 
0 1 2 3 
Total for each column 0    
Add columns for total score  
 
PHQ-9 Scores and Proposed Treatment Actions* 
PHQ-9 Score Depression Severity Proposed Treatment Actions 
0-4 None-minimal None 
5-9 Mild Watchful waiting; repeat PHQ-9 at follow-up 
10-14 Moderate Treatment plan, considering counseling, follow-up 
and/or pharmacotherapy 
15-19 Moderately Severe Active treatment with pharmacotherapy and/or 
psychotherapy 
20-27 Severe Immediate initiation of pharmacotherapy and, if 
severe impairment or poor response to therapy, 
expedited referral to a mental health specialist for 
psychotherapy and/or collaborative management 
* Kroenke, K. and Spitzer, R. (2002). Psychiatric Annals, 32, 509-521. 
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APPENDIX 18: CASE REPORT FORM 
Patient Initials: _____________________________                               Subject #:___________  
Depression Improvement Program Study 
Screening: 
Inclusion Criteria: 
 (Yes)         (NO) 
____     ____1) Ability to provide written informed consent 
____     ____2) Age > 18 years of age 
____     ____3) Diagnosis of Stroke or TIA                      
Exclusion Criteria: 
 (Yes)        (NO) 
____     ____1) Non-stroke Admission 
____     ____2) Severity of illness preventing participation at admission 
____     ____3) Refusal to consent 
Admission: 
Date of admission: ______/______/______       Time: ___________ 
                                Month               Day                 Year 
 
Informed Consent Signed by Patient or LAR: ______/______/______ 
                                                                            Month            Day                 Year 
Consent documented in chart: ______/______/______ 
 
Onset Date of Stroke: ______/______/______    LKN: ______________   
                                                        Month              Day                Year 
 
Sex: ______Male ______Female         
Race: _____Caucasian _____Black _____Hispanic _____Asian _____Other 
Education level: _________________ 
Work Status: Full-time____ Part-time_____ Retired_____ Housewife_____  
                                           Unemployed_____ Disabled_____ Student_____ 
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If working, what is occupation: ___________________________________? 
Date of Birth: ________/________/________        Age: ________ 
                          Month              Day                   Year 
Admission NIHSS: _________    Date: _______/_______/_______ 
                                                                 Month               Day                  Year 
Admission Modified Rankin Score: ________    Date: ______/_____/______                                                                                                                                                           
                                                                                                                                    Month       Day           Year 
Caregiver Name/Relationship: ______________________/________________ 
Phone Contact: __________________________________________                                                                                                                                                                                                                                                       
Email Contact: _____________________________________________ 
Past Medical History: 
 
 
 
 
 
 
Current Psychiatric Medications: 
Medication Dose Route Frequency 
    
    
    
 
Admission to NSICU: Date______/______/______    Time: _______ 
Admission to 6NSH floor: Date______/______/______    Time: _______ 
Admission PHQ-9 Score by Nursing: _______Date:___/____/____ Time: _____ 
 
Study Team 
Admission Patient PHQ-9 Score: __________ Date: ___/____/____ Time: _____ 
Admission Caregiver PHQ-9 Score: ______Date:____/_____/____ Time: _____ 
PHQ-9 Documented in chart: Yes _________No__________ 
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7 (+/- 3) Day Phone Call post Discharge 
---------------------------------------------------------------------------- 
Patient PHQ-9 Score: __________________ 
Caregiver Proxy PHQ-9 Score: __________________ 
Discharge Date: ___________ Diagnosis: ______________________ 
Location of Discharge: __________________ 
Length of Hospitalization (# of days):___________ 
Discharge NIHSS: _________________ 
Discharge mRS: _________________       Day 7 mRS: _________________ 
Physician documentation of PHQ-9:   Yes_______    No_______ 
Physician documentation of treatment: Yes_______ No_______ 
Patient Discharged on antidepressant: Yes_______   No________ 
Reason why not: __________________________________________________ 
Resident: _____________________ Attending: ____________________ 
Discharge Psychiatric Medications: 
Medication Dose Route Frequency 
    
    
If employed, has the patient returned to work?  Yes____   No____   N/A____  
Participating in rehab?   Yes_______   No_______ 
Therapies? _______PT   _______OT   _______ST 
Any changes in psychiatric medications since discharge? _____Yes   _____No 
If so, new or change in psychiatric medications: 
 
Medication Dose Route Frequency 
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30 (+/- 5) Day Phone Call or Clinic Follow-up 
---------------------------------------------------------------------------- 
Patient PHQ-9 Score: __________________ 
Caregiver Proxy PHQ-9 Score: __________________ 
mRS: _________________ 
If employed, has the patient returned to work?  Yes____   No____   N/A____ 
Has living situation changed?  Yes______   No______    
If so, how? _____________________________________________________ 
Participating in rehab?   Yes_______   No_______ 
Therapies? _______PT _______OT _______ST 
Hospitalized since enrollment? ______Yes     _______No 
If so, for what? ______________________________________ 
New diagnoses since enrolled?  ______Yes     _______No 
If so, what? ________________________________ 
Any changes in psychiatric medications since last phone call? ___Yes   ___No 
If so, new or change in psychiatric medications: 
Medication Dose Route Frequency 
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APPENDIX 19: ANTIDEPRESSANT MEDICATION CHART 
      Total Daily Dose Range (mg)     
Brand Name 
Trade 
Name Class 
Dose 
Range 
Startin
g Dose Titration 
Management 
Strategies Side Effects 
Citalopram Celexa SSRI 
10 to 
40mg 
10mg 
daily 
with 
food 
Increase by 
10mg every 2 
weeks 
Safe in the elderly, 
good initial therapy, 
few interactions, $4 
list, generic 
available 
Use with caution if history 
of hyponatremia or GI 
bleed (all SSRIs). Nausea, 
dry mouth, somnolence, 
diarrhea, tremor 
Escitalopram Lexapro SSRI 
5 to 
20mg 
5mg 
daily 
with 
food 
Increase by 
5mg 
increments 
Good in depression 
and anxiety 
Dizziness, insomnia, GI 
disturbance, weight 
changes, decrease sex drive  
Fluoxetine Prozac SSRI 
10 to 
80mg 
10mg 
daily 
for 6 
weeks 
Increase by 
10mg every 4 
weeks if no 
response after 
6 weeks 
Good in forgetful 
patients, long half-
life, $4 list, generic 
Nausea, Anorexia, Tremor, 
Insomnia, Anxiety 
Paroxetine Paxil SSRI 
10 to 
40mg 
10mg 
daily 
with 
food or 
QHS if 
sedatin
g 
Increase by 
10mg every 2 
weeks if no 
response after 
3 weeks 
Good in anxious 
patients (sedating) 
Discontinue syndrome - 
must be tapered. Increased 
drug interactions. Vision 
changes, dizziness, anxiety, 
insomnia, loss of appetite, 
constipation, dry mouth, 
decreased sex drive 
Sertraline Zoloft SSRI 
25 to 
200mg 
25mg 
daily 
with 
food 
Increase by 
50mg every 2 
weeks if no 
response after 
3 weeks 
Safe after MI, few 
interactions, 
generic available 
GI disturbance, weight 
changes, insomnia, 
decreased sex drive, 
dizziness, dry mouth 
Duloxetine Cymbalta SNRI 
20 to 
60mg 
20mg 
daily 
Increase to 
20mg BID 
after 1 week. 
If no response 
after 3 weeks 
increase to 
30mg BID 
Good in 
neuropathic pain; 
expensive 
Stress urinary incontinence, 
difficulty sleeping, diarrhea, 
dizziness, dry mouth, 
decrease appetite 
Venlafaxine Effexor SNRI 
37.5 to 
225mg 
37.5mg 
daily 
with 
food 
Increase to 
37.5mg BID if 
no response 
after 3 weeks 
(can be raised 
by 75mg every 
4 days) 
Good in anxious 
patients; can 
worsen HTN 
Discontinuation syndrome, 
nausea, sexual dysfunction, 
(insomnia, anxiety, HTN - 
occur at high doses) 
Mirtazapine Remeron 
Serotonin 
& 
Norepinep
hrine 
Antagonist 
15 to 
45mg 
7.5mg 
QHS 
Increase by 
7.5mg every 2 
weeks if no 
response after 
3 weeks 
Increases appetite, 
weight gain - use in 
malnourished 
patients; good in 
geriatrics, less 
sexual dysfunction 
Dizziness, strange dreams, 
vision changes, dry mouth, 
constipation, weight gain, 
dry mouth, 
Buproprion 
SR (avoid 
with history 
of seizure) 
Wellbutrin 
SR  NDRI 
100 to 
300mg 
100mg 
daily 
Increase to 
100mg BID if 
no response 
after 3 weeks 
Stimulating, less 
sexual dysfunction, 
least weight gain 
Dry mouth, Nausea, 
Insomnia, Constipation, 
Agitation,  May lower 
seizure threshold 
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APPENDIX 20: DIPS LETTER TO PRIMARY CARE PROVIDER 
 
PCP Physician Name                                                                                                 Date 
Address 
City, ST Zip 
 
Dear Colleague: 
Your patient, _____________________________, was recently admitted to UNC Healthcare on 
___________ with a diagnosis of _____________ (type of stroke).  During the admission, __________ 
consented to participate in the Depression Improvement Program for Stroke (DIPS) Study.   
Post-stroke depression (PSD) is common, occurring in at least one-third of patients; however, it is under 
recognized and under treated.  PSD is a serious complication and is significantly associated with a 
negative impact on recovery and higher mortality rates (Towfighi, 2016). 
The Patient Health Questionnaire (PHQ-9) is used to assess patients for depression, incorporating DSM-V 
diagnostic criteria with depressive symptoms in a self-report tool.  Williams screened for depression in 
316 stroke patients and found that the PHQ-9 at a score of > 10 had a sensitivity of 91% and specificity 
of 89% for major depression and a 78% sensitivity and 96% specificity for any depression diagnosis. 
Attached is information about the PHQ-9, which includes treatment recommendations.   
This letter is to inform you that, _________________ has scored a _____________on the PHQ-9.  The 
patient and family is aware of the score and has been encouraged to discuss this at their next medical 
appointment. 
If you have any questions, please do not hesitate to contact me. 
Sincerely, 
Susan E. Wilson RN, MSN, C-ANP 
Associate Professor, Department of Neurology 
Adult Stroke Nurse Practitioner 
University of North Carolina Stroke Center 
CB# 7025 170 Manning Drive 
Physicians Office Building, Room G178 
Chapel Hill, NC 27599-7025 
Phone: (919) 843-2387 
Fax: (919) 843-3252 
 
References: 
1. Towfighi A, et al. 2016. Poststroke depression: a scientific statement for healthcare professionals 
from the American Heart Association/American Stroke Association. Stroke 47:1-14. 
2. Williams, L., et al. 2005. Performance of the PHQ-9 as a screening tool for depression after 
stroke. Stroke,36:635-638.  
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APPENDIX 21: DIPS PHYSICIAN SATISFACTION QUESTIONNAIRE 
Depression Improvement Program in Stroke Program 
(DIPS) Physician Satisfaction Questionnaire 
Please answer the following questions about the post-stroke depression (PSD) 
project and help the stroke program continue improving care  
 
 Questions Yes No Not 
sure 
1 Do you believe many of your stroke patients need help with 
depression? 
   
2 Did you receive education/information about PSD and the 
importance of treatment for depression symptoms in stroke 
patients? 
   
3 Do you explain PSD to your patients/families?    
4 Do you understand how to implement treatment for PSD 
based on the PHQ-9 score? 
   
5 Do you know how to find the PHQ-9 score within EPIC?    
 
Please provide your thoughtful answer to the last two questions: 
 
1. What went well with the implementation of DIPS program? 
 
 
2. What could be improved with the PHQ-9 assessment/documentation process? 
 
Prior to project implementation, assessment of depression symptoms averaged 23% and 
treatment occurred less than 30% of the time.  Since project implementation PSD, 
assessment is approximately 88% and treatment rate has increased to 70%.   
 
Thank you for the excellent care you provide! 
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APPENDIX 22: DIPS NURSING SATISFACTION QUESTIONNAIRE 
Depression Improvement Program in Stroke Program 
(DIPS) Nursing Satisfaction Questionnaire 
Please answer the following questions about the post-stroke depression (PSD) 
project and help the stroke program continue improving care  
 Questions Yes No Not 
sure 
1 Do you believe many of our patients need help with 
depression? 
   
2 Did you receive education/information about PSD and the 
importance of screening for depression symptoms in 
stroke patients? 
   
3 Do you explain PSD to your patients/families?    
4 Since implementation of the depression, improvement 
program in stroke (nurses screening using the PHQ-9 and 
physicians considering treatment based on the score) is 
there more focus from the physician team on PSD? 
   
5 Do you report off the PHQ-9 score during shift report?      
 
Please provide your thoughtful answer to the last three questions: 
1. What barriers do you face in assessing your stroke patients for depression? 
 
 
2. What went well with the implementation of DIPS program? 
 
 
Prior to project implementation, assessment of depression symptoms averaged 23% and 
treatment occurred less than 30% of the time.  Since project implementation PSD, 
assessment is approximately 88% and treatment rate has increased to 70%.   
 
Thank you for the excellent care you provide! 
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APPENDIX 23: PHYSICIAN COMMENTS TO QUESTIONS #6 AND #7  
 
Question # 6: What Went Well with the Implementation of DIPS Program?  
• “Standardization of obtaining PHQ-9” 
• “Increased awareness of PSD, its assessment, and its treatment. Good review of common 
antidepressants” 
 
• “Excellent explanation of need and how to screen.  Also good follow-up” 
• “Increasing recognition of depression with stroke” 
• “More recently, nursing staff seems to be much more consistent about getting PHQ-9 
scores on stroke patients. Residents seem to pay more attention to the score if they are 
reminded about it earlier in the week” 
 
• “Information provided by stroke team (drug list and treatment algorithm) and attending 
physician support”  
 
 
 
Question #7: What Could Be Improved with the PHQ-9 Assessment/Documentation 
Process? 
 
• “Make the PHQ-9 easier to find in the system” 
• “Review of where to find PHQ-9 in EPIC” 
• “With turnover, would continue with training as time passes” 
• “Would encourage nursing staff to communicate high PHQ-9 scores to the physicians to 
make them aware earlier, as sometimes physicians don’t review the PHQ-9 until at 
discharge” 
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APPENDIX 24: NURSING COMMENTS TO QUESTIONS #6 AND #7 
 
Question #6: What Barriers Do You Face in Assessing Your Stroke Patients for 
Depression? 
 
 
• “Inability to assess due to patient’s cognitive or aphasic status. Family cannot answer on 
patients behalf” 
 
• “Patient unable to communicate or no family present to ask the questions” 
• “The severity of the strokes causing cognitive deficits” 
• “Their alertness and cognitive ability” 
• “No family or patient is confused” 
• “Cognitive impairment; families often not good resource to answer PHQ-9” 
• “Sometimes the patients don’t want to talk about it and it feels robotic asking all of those 
questions” 
 
• “Some patients are not “with it” enough to be able to complete the questionnaire. Busy 
with other things, forget to assess for that piece. I haven’t seen anyone do anything with 
the information gathered from the PHQ-9”  
 
• “Aphasic patients. Also, many patients found that the questions were written in a way 
that confused them – not straightforward” 
 
• “Aphasia and confusion, time” 
• “Communication – aphasia, time during the shift to approach this with patient – it 
requires a relationship to be developed” 
 
• “Difficulty with patients having aphasia – otherwise none” 
• “Cognition problems” 
• “EPIC – have to go to different tabs to assess and document. It is confusing having the 
PHQ-2 in our stroke tab yet we are expected to document the PHQ-9 in a different tab” 
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Question #7: What Went Well with the Implementation of DIPS Program? 
 
• “Having a place to record PHQ-9 in EPIC so the entire care team could have access to the 
scores” 
 
• “Patient and staff is becoming more aware of depression after stroke” 
• “Effective unit compliance” 
• “It was clear on EPIC” 
• “I’m a new nurse, so it’s too early for me to tell” 
• “Honestly, I don’t know very much about the DIPS program” 
• “Easy for RN to complete during admission and easy follow-up to stroke team” 
• “Creating the stroke research tab; recognizing and rewarding staff for their work” 
• “Great education about program, easy to use flowsheet” 
• “Stroke NP providing education and support. Having her on the unit answering questions 
and assisting with performing the PHQ-9 was helpful” 
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